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Summary of the thesis 
Pancreaticoduodenectomy (PD), a complex surgical procedure for resecting tumors of the 
pancreatic head, distal bile duct or periampullary region, is associated with a considerable 
morbidity. Postoperative pancreatic fistula (POPF), the main contributor, is caused by leakage from 
the pancreatico-enteric anastomosis and ranges from 15 to 26%. If not controlled promptly, POPF 
may lead to a complex postoperative course with septic or hemorrhagic complications, organ failure 
and increased mortality. Although multiple approaches to decrease POPF rates have been reported, 
an effective preventive strategy has not been found. The aims of this thesis were to study the 
contributing factors and early diagnostic markers of clinically relevant POPF, and to formulate 
predictive models that may facilitate clinical management of patients undergoing PD. 
In study I, a prospective observational cohort study on 48 non-consecutive PD patients 2007-10, 
local metabolite changes and protease activation in the proximity of the pancreaticojejunostomy 
(PJ) were measured by microdialysis to investigate the pathophysiology of POPF. In patients 
subsequently developing POPF, high glycerol and lactate/pyruvate (LP) ratio levels, low glucose 
concentrations and presence of trypsinogen activation peptides were observed before any POPF 
symptoms appeared. The fact that glycerol level peaks preceded the elevations in LP ratios 
suggested that the early glycerol release in POPF patients was not initiated by local ischemia. 
In study II, a prospective observational cohort study on 110 non-consecutive PD patients 2008-10, 
the predictive impact of a standardized intraoperative assessment of pancreatic consistency (PC) 
and pancreatic duct diameter (PDD) on the development of POPF was investigated. Combining 
both characteristics in a composite classification, the risk for POPF or fluid collections could be 
stratified as ‘high’ (softer PC and smaller PDD, incidence of associated morbidity 51%), 
‘intermediate’ (softer PC or smaller PDD, 26%) or ‘low’ (no risk factors, 2%). Only patients with 
smaller PDD developed severe POPF. 
In study III, a prospective observational cohort study on 195 consecutive PD patients 2008-10, the 
importance of POPF for PD-associated morbidity was evaluated by comparing the predictive impact 
of an intraoperative pancreatic risk assessment (IPRA) with the generally applicable “Physiological 
and Operative Severity Score for the enUmeration of Mortality and Morbidity” (POSSUM). 
Although the POSSUM-estimated risk corresponded with observed morbidity for the entire cohort, 
individual and grouped POSSUM risk estimates did not reveal any association with the incidence or 
severity of overall morbidity. However, the IPRA model identified patients with high POPF-risk 
and was even significantly associated with the incidence and severity of overall morbidity.  
In study IV, a prospective observational cohort study on 315 consecutive PD patients 2008-12, the 
analysis of pancreatic amylase from intraabdominal drainage (DPA) as an early diagnostic marker 
of POPF following PD was evaluated. DPA at selected cut-off levels was proven to be superior to 
that of plasma pancreatic amylase in predicting clinically relevant POPF. A model combining DPA 
and C-reactive protein (CRP) had the highest POPF-predictive impact. Persistently raised CRP 
levels on POD 3 proved to be an independent indicator for subsequent POPF development. 
In summary, standardized intraoperative pancreatic risk assessment (IPRA) constitutes a central tool 
for surgical decision making in the risk management of patients undergoing PD. It had a stronger 
predictive impact on the incidence and severity of overall postoperative morbidity than an 
established generally applicable risk adjustment model (POSSUM).  Analyses of local metabolite 
concentrations or pancreatic amylase levels from intraabdominal fluids in the proximity of the PJ 
could serve as diagnostic markers for subsequent POPF development at an early subclinical stage.  
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I INTRODUCTION 
Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC), one of the most lethal human 
cancers, remains an unsolved major health problem (Vincent et al., 2011). 3600 new cases 
occurred in the Nordic Countries between 2006 and 2010 (1752 in males, 1848 in females), 
while 4014 deaths were registered (1893 males and 2121 females, incidence 7.5 and 6.2, 
mortality 7.9 and 6.5 per 100.000, respectively).  The fact that mortality rates are higher 
than incidence rates reflects the underreporting of new pancreatic cancer cases in 
individuals older than 70 years (Lambe et al., 2011). In Sweden, pancreatic cancer is the 
14th most common cancer form with 825 new cases (1.8% of all new cancer cases) but the 
5th most common cancer mortality behind prostate, lung, breast and colorectal cancer with 
1575 deaths, representing 7.1% of all cancer deaths per year (NORDCAN; ANCR). 
Despite huge efforts, clinicians and researchers have not been able to improve PDAC 
survival rates. Surgery as the cornerstone of treatment with curative intent can be offered to 
only 15-20% of patients at the time of diagnosis (Li et al., 2004). Even with complete local 
surgical tumor clearance, the relapse rate remains high with poor outcomes at 5 years (Sohn 
et al., 2000; Yeo et al., 1997a; Neoptolemos et al., 2012). Cancer detection at earlier stages 
might give more patients access to surgery; however, most critical to improving the 
outcomes of resected PDAC is the development of effective systemic therapies. Future 
development of curative intent therapy in randomized clinical trials (RCT) is limited to 
those patients with non-disseminated disease, and undergoing a strictly assessed R0 
resection (Crane et al., 2010). 
Besides achieving complete tumor clearance, a major objective in the research field of 
pancreatic surgery is to control the high post-pancreatectomy morbidity, which is 
predominated by two major complications; delayed gastric emptying (DGE) and post-
operative pancreatic fistula (POPF). The latter is still challenging; if not controlled 
immediately, POPF may lead to severe secondary morbidity and significantly increased 
mortality (Hackert et al., 2011a). Patients with other cancer forms than PDAC and the 
associated better survival rates have the highest risk of developing POPF (Pratt et al., 
2008a).  
The intensive research on understanding pathways of cancer development, early detection 
strategies for PDAC, identification of cancer precursors, and the management of patients in 
high-volume centers with surgical and oncologic expertise may show promise to improve 
outcomes (Li et al., 2004; Saif, 2011). However, the extension of surgical indications, 
shifting from curative-intent towards cancer-preventive surgery, might even implicate a 
change of the patient profile. Pancreatic surgeons will have to respond to an increasing 
demand for preventive surgery in younger, apparently healthier, more hesitant patients, 
with a greater need of information about the legitimacy of surgery in their individual cases. 
A lesser acceptance of possible severe postoperative complications will necessitate radical 
improvements to control surgical complications. Theoretically, the ability to control POPF 
could change the public picture of pancreatic resections and contribute to rationalizing 
more aggressive preventive surgical strategies in the fight against pancreatic cancer. 
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Anatomical aspects 
The pancreatic gland is a retroperitoneal organ centrally located in the upper abdomen and 
ventral to the mesenteric vessels, extending from the pancreatic head in the C-loop of the 
duodenum to the pancreatic tail in the splenic hilum. In an adult, the pancreas is 15-20 cm 
long and weighs 75-100 g. The fact that even a minor surgical trauma to the pancreas can 
result in the release of pancreatic enzymes and cause pancreatitis, illustrates the importance 
of anatomic knowledge of the pancreatic gland and its surrounding structures for surgeons 
(Fisher W.E., 2010). 
The pancreatic gland develops in the fourth week of fetal life by a fusion of the dorsal and 
ventral pancreatic bud from the caudal part of the foregut. With gut rotation, the ventral bud 
rotates around the posterior side of the duodenum to fuse with the dorsal bud. In the adult 
pancreas, both the caudal head portion and the uncinate process are derived from the ventral 
bud, whereas the cranial head portion, body and tail are derived from the dorsal bud. The 
ducts of the dorsal and ventral pancreas join to form the main pancreatic duct (duct of 
Wirsung); a smaller part of the dorsal duct persists in the pancreatic head as an accessory 
duct (duct of Santorini). In 5–15% of the population, the ventral and dorsal ducts fail to 
fuse resulting in a pancreas divisum and pancreatic drainage mainly through the duct of 
Santorini and through the minor papilla into the duodenum (Doherty, 2010).  
 
The pancreatic regions and their blood supply 
Pathological lesions in the pancreas are typically described in relation to four pancreatic 
regions (head, neck, body, and tail). The pancreatic head with the uncinate process lies 
within the C-loop of the duodenum and is associated medially to the mesentery of the 
transverse colon. The retroperitoneum behind the head of the pancreas contains the caval 
vein with the left renal vein and the aorta with the right renal artery.  
The neck of the pancreas lies over the mesenteric root, where the splenic vein and superior 
mesenteric vein (SMV) join to continue in the hepatoduodenal ligament as the portal vein 
(PV). At the inferior border, the inferior mesenteric vein (IMV) joins the splenic vein near 
its junction with the SMV, or the SMV directly. The superior mesenteric artery (SMA) 
leaves the aorta above the crossing of the left renal vein and continues in the root of the  
mesentery to the left of the SMV. The inferior pancreaticoduodenal artery branches from 
the SMA and divides into the anterior and posterior inferior pancreaticoduodenal arteries 
which form the arterial pancreatic arcade giving off numerous branches to the duodenum 
and pancreatic head. 
The pancreatic head contains the most distal part of the common bile duct (CBD). The 
intra-pancreatic CBD joins the main pancreatic duct at the ampulla of Vater. The uncinate 
process and the head of the pancreas wrap around the right side of the SMV/PV. Venous 
branches draining the pancreatic head and uncinate process enter along the right lateral and 
posterior sides of the SMV/PV (Fisher W.E., 2010). As there are usually no anterior venous 
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tributaries, a dissection plane can be developed between the neck of the pancreas and the 
SMV/PV. The gastroduodenal artery (GDA) leaves from the common hepatic artery and  
continues as the superior pancreaticoduodenal artery behind the first portion of the 
duodenum. It branches into the 
anterior and posterior superior 
pancreaticoduodenal arteries. It is 
not possible to resect the pancreatic 
head without devascularizing the 
duodenum, unless a rim containing 
the pancreaticoduodenal vascular 
arcade is preserved (Fisher W.E., 
2010). Variations in the anatomy of 
the right hepatic artery, common 
hepatic artery, or GDA occur in 20% 
of patients (Michels, 1962), and the 
preoperative knowledge of the 
individual anatomy regarding the 
arterial liver supply is important for 
surgical and oncological reasons. 
Once the gastrocolic omentum is 
divided and the omental bursa is 
opened, the body and tail of the 
pancreas is visible posterior to the 
stomach, and anterior to the splenic 
artery and vein. Multiple small 
venous branches from the pancreatic 
body and tail drain to the splenic 
vein running in a groove on the 
posterior aspect. The splenic artery 
branches from the celiac trunk and 
continues superior to the vein along 
the posterior superior edge of the 
pancreatic body and tail. The body 
of the pancreas is situated ventral to 
the aorta at the origin of the SMA 
and the neck of the pancreas ventral 
to the vertebral body of L1 and L2. 
Blunt anteroposterior trauma can compress the neck of the pancreas against the spine and 
cause a pancreatic “fracture” with parenchymal and/or ductal injury (Rekhi et al., 2010). 
The pancreatic tail contains the portion from anterior to the left kidney to the hilum of the 
spleen (Fisher W.E., 2010). The body and tail of the pancreas are supplied by multiple 
branches of the splenic artery. The inferior pancreatic artery, ordinarily branching from the 
SMA, runs along the inferior border of the body and tail of the pancreas, parallel to the 
splenic artery, forming arcades within the body and tail of the pancreas, and accounting for 
Table 1. Regional abdominal lymph nodes. 
1 Right paracardial 
2 Left paracardial 
3 Lesser curvature 
4sa Short gastric vessels 
4sb Left gastroepiploic vessels 
4d Right gastroepiploic vessels 
5 Suprapyloric 
6 Infrapyloric 
7 Left gastric artery 
8a Common hepatic artery anterosuperior 
8p Common hepatic artery posterior 
9 Celiac artery 
10 Splenic hilum 
11p  Proximal splenic artery 
11d Distal splenic artery 
12a  Hepatoduodenal ligament (LHA) 
12b  Hepatoduodenal ligament (CBD) 
12p  Hepatoduodenal ligament (PV) 
13 Pancreatic head posterior surface 
14v Superior mesenteric vein 
14a Superior mesenteric artery 
15 Middle colic vessels 
16a1 Aortic hiatus 
16a2 Abdominal aorta CT to LRV 
16b1 Abdominal aorta LRV to IMV 
16b2  Abdominal aorta IMV to AB 
17 Pancreatic head anterior surface 
18 Pancreas inferior margin 
19 Infradiaphragmatic  
20 Diaphragm esophageal hiatus 
110 Lower thorax Paraesophagea 
111 Supradiaphragmatic  
112 Posterior mediastinal 
 
Map of lymph node stations (Kawarada, 1998). 
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the rich blood supply of the organ. The venous drainage of the pancreas follows a similar 
pattern (Fisher W.E., 2010). 
 
Lymphatic drainage and innervation 
The widespread and diffuse lymphatic drainage from the pancreas contributes to early 
lymphatic invasion and dissemination in pancreatic cancer. The profuse network of lymph 
node stations has been mapped systematically (Kawarada, 1998). The pancreatic lymphatic 
system communicates with lymph nodes in the mesentery of the transverse colon and the 
proximal jejunum. In the pancreatic parenchyma, the acinar cells responsible for exocrine 
secretion and the islet cells responsible for endocrine secretion are stimulated by 
parasympathetic and inhibited by sympathetic nerves.  In several studies about pancreatic 
nociception, the rich supply of afferent sensory fibers in the pancreatic parenchyma has 
been made responsible for the intense pain associated with advanced pancreatic cancer, as 
well as acute and chronic pancreatitis (Fisher W.E., 2010; Bradley & Bem, 2003). 
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Physiological aspects 
The endocrine (2% of the cells in the pancreatic gland) and exocrine (85%) functions of the 
pancreatic gland are not functionally separated but components of a single complex 
regulatory feedback system for digestive enzyme and hormone secretion. Although it is 
possible to live without the pancreas if insulin and digestive enzymes are substituted, the 
loss of the pancreatic regulation after a total pancreatectomy leads to severe impairments in 
digestive function. Although only 20% of the normal pancreatic parenchyma is required to 
prevent functional insufficiency (Leahy et al., 1984), many patients undergoing pancreatic 
resection have pancreatic remnants with impaired endocrine and exocrine function, and 5-
11% develop pancreatic fibrosis and atrophy due to malfunction of the pancreatico-enteric 
anastomosis (Morgan et al., 2010; Reid-Lombardo et al., 2007a) or insufficient pancreatic 
stimulation.  
 
Exocrine function 
The external secretion of the pancreas is stimulated by the hormones secretin and 
cholecystokinin (CCK) and by parasympathetic vagal discharge. Pancreatic juice is an 
alkaline (pH 7.0–8.3) and isosmotic solution of 1–2 liters per day containing the secretions 
of acinar and duct cells. The acinar cells secrete amylase, proteases and lipases, enzymes 
responsible for the digestion of carbohydrate, protein, and fat, respectively. Unlike the 
endocrine islet cells that specialize in the secretion of one hormone type, individual acinar 
cells are capable of secreting all enzyme types. Due to a sequential regulation of secretion, 
the ratio of different enzymes secreted can be adjusted to the mix of food being digested. 
Pancreatic juice helps to neutralize gastric acid in the duodenum and adjusts luminal pH to 
a level that provides optimal conditions for the catalytic activity of the enzymes. Lipase and 
amylase are stored and secreted in active forms. Pancreatic amylase completes the digestive 
process that was started by salivary amylase. Phospholipase A and the proteases are 
secreted as an inactive proenzyme and activated in the duodenum (Davenport, 1982). 
Proteolysis and lipolysis 
The conversion of trypsinogen into active trypsin and the inactive cleavage product 
trypsinogen activation peptide (TAP) occurs at the intestinal brush border, catalyzed by 
enterokinase, an enzyme which is produced by the duodenal mucosal cells (Rinderknecht, 
1993a). Trypsin, in turn, activates other proteolytic enzymes. The separate storage of 
proteases from other cell proteins, the secretion of proenzymes that require activation, and 
the presence of proteolytic enzyme inhibitors in the pancreatic juice and in the pancreatic 
parenchyma prevent the pancreas from autodigestion. A failure to express the pancreatic 
secretory trypsin inhibitor (PSTI), also known as serine protease inhibitor Kazal-type 1 
(SPINK1) or tumor-associated trypsin inhibitor (TATI), is one of the causes of hereditary 
pancreatitis (Chen et al., 2000). Trypsinogen is expressed in several isoforms. Trypsinogen-
1, also known as cationic trypsinogen, is the main isoform of trypsinogen and encoded by 
the PRSS1 gene. Mutations on the cationic trypsinogen gene can result in the premature 
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intrapancreatic activation of trypsinogen, which accounts for about two thirds of cases of 
hereditary pancreatitis (Mitchell et al., 2003). Trypsin activates chymotrypsin, elastase, 
carboxypeptidase A and B, and phospholipase, which together with other pancreatic lipases 
(pancreatic triglyceride lipase, carboxylester lipase) hydrolyze phospholipids and 
triglycerides into the end products glycerols and free fatty acids. Trypsin, chymotrypsin, 
and elastase cleave bonds between amino acids within a target peptide chain, and 
carboxypeptidase A and B cleave amino acids at the end of peptide chains. The individual 
amino acids and small dipeptides are then actively transported into the intestinal epithelial 
cells. Pancreatic lipase hydrolyzes triglycerides to 2-monoglyceride and fatty acid and 
phospholipase A2 hydrolyzes phospholipids. All lipases require bile salts to be active and 
are enhanced by co-lipase. Fat is hydrolyzed by carboxylic ester hydrolase and cholesterol 
esterase and packaged into micelles for transport into the intestinal epithelial cells, where 
the fatty acids are reassembled and packaged inside chylomicrons for transport through the 
lymphatic system into the blood (Doherty, 2010). 
Table 2. Exocrine Pancreatic Enzymes. 
Elastase 
Cleaves carboxyl side of peptide bonds after small amino acid residues 
(alanine, glycine, serine) to produce oligopeptides 
Trypsinogen/ 
Trypsin 
Cleaves internal bonds at lysine or arginine residues to produce 
oligopeptides, activates other pancreatic proenzymes  
Chymotrypsinogen/ 
Chymotrypsin 
Cleaves carboxyl side of peptide bonds at aliphatic amino acid residues 
to produce oligopeptides 
Pancreatic carboxypeptidase 
(A1, A2, and B) 
Removes aromatic amino acids from carboxyl terminal end of protein or 
peptide chains, produces Arginine and Lysine 
Pancreatic lipase 
Cleaves triacylglycerol "fat" molecules into glycerol, two free fatty acids, 
and monoglycerides 
Pancreatic amylase Cleaves starches 
Phospholipase A2 Cleaves phospholipid molecules at the second glycerol carbon 
Lysophospholipase 
Cleaves 2-lysophosphatidylcholine to produce glycerophosphocholine (a 
precursor of acetylcholine) 
Cholesterol esterase Cleaves fatty acid 
 
Acinar secretion 
An acinus consists of about 40 acinar cells. The duct cells, located near the center of the 
acinus (centroacinar cells), are responsible for the secretion of fluid and electrolyte in the 
pancreatic juice and contain carbonic anhydrase, an enzyme needed for bicarbonate 
secretion. Secretin-stimulated bicarbonate secretion buffers the acidic fluid entering the 
duodenum from the stomach. Chloride secretion varies inversely with the bicarbonate 
secretion. Sodium and potassium levels in the pancreatic secretion are constant and 
independent of the secretory rate. CCK stimulates bicarbonate secretion to a much lesser 
extent than secretin but potentiates secretin-stimulated bicarbonate secretion and augments 
the secretion of insulin. Somatostatin, pancreatic polypeptide (PPP), and glucagon of the 
endocrine pancreas inhibit exocrine secretion (Harris, 1994). The acinar cells release 
pancreatic enzymes into the lumen of the acinus, where they join with the fluid and 
bicarbonate secretions of the centroacinar cells. The pancreatic juice drains into small 
intercalated ducts and interlobular ducts, where fluid is added and electrolytes are adjusted, 
and into side branches that empty into the main pancreatic duct. Recurrent inflammation, 
trauma or manipulation, contributes to destruction of the branching structure, and together 
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with acinar or mesenchymal cell damage to the development of inter-, intralobular fibrosis 
and exocrine pancreatic insufficiency (Bro-Rasmussen et al., 1956; Kloppel et al., 2004). 
 
Endocrine function 
There are at least one million islets of Langerhans in the normal adult pancreas. Larger 
islets are located in proximity to the major arterioles and smaller islets are embedded in the 
pancreatic parenchyma. Most islets contain 3000 to 4000 cells of five major types: alpha 
cells that secrete glucagon, beta cells that secrete insulin, delta cells that secrete 
somatostatin, epsilon cells that secrete ghrelin, and PP cells that secrete PPP.  
Insulin 
Stored insulin can be released rapidly during a first secretion phase. The second phase is a 
sustained release due to ongoing production of new insulin. Insulin synthesis is regulated 
by plasma glucose levels, neural signals, and the paracrine influence of other islet cells. 
Glycogenolysis, fatty acid breakdown, ketone formation and hepatic glucose production is 
inhibited by Insulin, whereas protein synthesis is stimulated and glucose transport into cells 
facilitated (Ebert, 1987).There is a considerable amount of functional reserve in insulin 
secretory capacity. If the remaining portion of the pancreas is healthy, about 80% of the 
pancreas can be resected without the patient becoming diabetic; however, in chronic 
pancreatitis or other disease conditions, even smaller pancreatic resections can result in 
diabetes (Leahy et al., 1984). Insulin deficiency (type I diabetes) results in an up-regulation 
of insulin receptors, leading to an enhanced insulin sensitivity. Type II diabetes is 
associated with insulin resistance, down-regulation of insulin receptors and relative 
hyperinsulinemia (Doherty, 2010). 
Glucagon, somatostatin and pancreatic polypeptide 
Glucagon is a peptide that promotes hepatic glycogenolysis and gluconeogenesis and 
counteracts the effects of insulin. Insulin and somatostatin inhibit glucagon secretion in a 
paracrine fashion within the islets. The same neural impulses that regulate insulin secretion 
also regulate glucagon secretion, so that the two hormones work together in a balance of 
actions to maintain glucose levels (Brunicardi et al., 1987). Somatostatin is a peptide with a 
wide anatomic distribution and is important in many regulatory processes throughout the 
body. Endocrine release of somatostatin occurs during a meal by intraluminal fat and the 
acidification of the gastric and duodenal mucosa. Acetylcholine from the cholinergic 
neurons inhibits somatostatin release (Brunicardi et al., 1994). Pancreatic polypeptides 
(PPP), discovered during the process of insulin purification (Kimmel et al., 1968), are 
known to inhibit bile secretion, gallbladder contraction, and secretion by the exocrine 
pancreas. A number of studies suggest that PPP control glucose levels through the 
regulation of hepatic insulin sensitivity at the transcriptional level (Saltiel, 2001; Asakawa 
et al., 2003). Deficiencies in PPP secretion due to proximal pancreatectomy or severe 
chronic pancreatitis are associated with diminished hepatic insulin sensitivity due to a 
reduced number of hepatic insulin receptors (Seymour et al., 1998). 
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Historical aspects 
The first anatomical descriptions of the pancreas have been attributed to Herophilus of 
Chalcedon in the third century BC (McClusky et al., 2002; Busnardo et al., 1983) . The 
observation that it did not consist of cartilage or bone prompted Ruphos of Ephesus to name 
the organ “pancreas” (Greek “pan” means “all”; Greek “kreas” means “flesh”) two hundred 
years later (Howard, 2003).  
 
Pancreatic research 
In the 16th century, in the fifth book of his opus “De humani corporis fabrica” (Fabric of the 
Human Body), Vesalius referred to the pancreas as a “glandulous organ” postulating that it 
exerted a protective effect on the stomach by serving as a cushion (Busnardo et al., 1983). 
The main pancreatic duct was described by Wirsung in 1642, not understanding its 
function, and the accessory pancreatic duct by Santorini in 1775 (Stern, 1986). In 1720, 
Vater described the duodenal ampulla, and in 1887, Oddi the papillary sphincter (Howard et 
al., 1998).  
The first discoveries in pancreatic physiology were made in the late 17th century. In 1671, 
Sylvius de le Boe proposed in his work “Praxeos medicae idea nova”, that digestion was a 
multistep process including a fermentation through saliva in mouth and stomach, in a 
second phase involving the pancreas, followed by the passage of chyle into the lymphatic 
and the venous system, and eventually, into the right side of the heart (Kidd, 1999). In 
contrast, Brunner proposed some years later that specialized duodenal glands were the 
major source of digestive juice secretion, and that the pancreas was not a vital organ. In 
1682, Peyer concluded that the lymphatic nodules in the walls of the ileum and Brunner’s 
glands were main adjuncts to digestion, and the pancreas was a minor contributor 
(Busnardo et al., 1983). This reductionist modification of Silvius’ innovative theories 
delayed the progress of pancreatic research for years (Pannala et al., 2009). In 1815, Marcet 
discovered lipase, and in 1876, Kuhne discovered trypsin and its role in the digestion of 
proteins.  In 1843, Eberle showed that pancreatic juice emulsified fat, and one year later, 
Valentin demonstrated its activity on starch (Kidd, 1999). In 1848, Bernard proposed that 
gastric digestion was "only a preparation act" and that pancreatic juice emulsified fatty 
foods. In addition, he revealed the pancreatic contribution to converting starch into sugar, 
and its solvent action on the "proteides that have not been cleaved in the stomach" (Kidd, 
1999). The regulative concept of pancreatic secretion was initially addressed by Pavlov in 
“The Work of the Digestive Glands” in 1897, suggesting that the vagal nerve was a 
predominant neurological regulator (Pavlov, 1953). In 1869, Langerhans had published his 
“Contribution to the Microscopic Anatomy of the Pancreas”, he was the first to describe the 
structure of the islet tissue, which Laguesse in 1893 named the islands of Langerhans 
(Busnardo et al., 1983). In 1902, Bayliss and Starling demonstrated that pancreatic 
secretion was controlled by chemical messengers, which led to the introduction of 
“hormones” (derived from the Greek “hormonos” meaning ‘I arouse to excitement’) and 
the putative agent "secretin" (Bayliss, 1902). In 1922, Insulin was discovered and isolated 
9 
 
(Banting et al., 1922). The discovery of the serum amylase test by Elman in 1927 was a 
great contribution to the differential diagnosis of acute pancreatitis (Busnardo et al., 1983; 
Elman, 1937). Further developments included the discovery of CCK by Ivy and Oldberg in 
1928 (Mutt, 1994) and their understanding that pancreatic secretion was regulated by a 
complex chemical messenger system (Pannala et al., 2009).  
 
Surgical pioneers 
Most of the early pancreatic surgeons resected only portions of the duodenum and pancreas. 
Allen Oldfather Whipple was the first surgeon to perform a complete resection of the 
duodenum and head of the pancreas; in 1935 in a  two-stage, and in 1940 in a one-stage 
procedure (Busnardo et al., 1983).   
The first pancreatic head resection with transection of the pancreatic duct was performed by 
Biondi in 1894, resecting a pancreatic fibroadenoma and re-approximating the duodenum 
and the pancreatic remnant. The postoperative course was complicated by biliary and 
pancreatic fistula which eventually resolved. In 1898, Codivilla performed the first reported 
pancreaticoduodenectomy (PD) on a 46 year old male with a locally advanced cancer, 
removing parts of the pancreas, duodenum, distal stomach and distal bile duct. Continuity 
was restored using a Roux-en-Y gastrojejunostomy and a cholecystojejunostomy excluding 
the pancreatic stump. The patient died at 18 days from steatorrhea-induced cachexia 
(Schnelldorfer et al., 2008). In 1898, Halsted performed the first successful resection for 
ampullary cancer by resecting portions of the duodenum and pancreas in a 60 year old 
female with painless jaundice. The operation included a CBD exploration, transduodenal 
papillectomy and reanastomosis of the pancreatic and bile duct (Are et al., 2011).  
In 1905, Garre re-approximated the capsule of a traumatically cleaved pancreatic gland 
with silk sutures. The duct was not sutured and the result was a pancreatic fistula which 
resolved after two months. A similar technique was used in the first successful partial PD 
performed by Erhardt in 1907 (Howard, 2003). In 1909, Kausch applied Kocher’s 
maneuver in a resection of the duodenum en bloc with a portion of the pancreas, 
establishing continuity by a pancreaticoduodenostomy. The patient recovered initially from 
a pancreatic fistula, but died nine months later due to cholangitis (Whipple, 1946). In 1912, 
Hirschel performed a one-stage resection removing parts of the duodenum, ampulla, head 
of pancreas and the lower part of the CBD. Continuity was established by re-implanting the 
pancreatic duct into the duodenum, a posterior gastroenterostomy and bridging of the 
common bile duct to the duodenum by a rubber tube. The patients jaundice was relieved 
and he lived for one year. The cause of death or fate of the rubber tube was unknown as an 
autopsy was never performed (Whipple, 1946). In 1922, Tenani performed a successful 
two-stage resection for ampullary carcinoma in a 43-year-old male by a posterior 
gastroenterostomy and choledochoduodenostomy to the lower duodenum in a first stage, 
and excising portions of the duodenum, and pancreatic head in a second stage, establishing 
continuity by a pancreaticoduodenostomy. The patient recovered after a severe post-
operative course and lived for 3 years (Whipple, 1963).  
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Allen Oldfather Whipple 
The first complete duodenectomy and pancreatic head resection was reported in 1935 by 
Whipple, Parsons and Mullins from Columbia Presbyterian Hospital in New York who had 
operated three patients for ampullary cancer in a two-stage procedure including a radical 
resection of the duodenum and head of the pancreas for ampullary cancer. The third patient 
underwent a total duodenectomy and excision of a large portion of the head of the pancreas. 
The first patient died shortly after the operation due to consequences of anastomotic 
breakdown, the others lived for 9 and 24 months and died of cholangitis and liver 
metastasis, respectively (Whipple, 1946; Whipple et al., 1935). In 1937, Brunschwig 
performed the first radical anatomic pylorus-preserving PD with complete transection of the 
pancreatic head to the right of the SMV due to pancreatic carcinoma in two stages 
(Brunschwig, 1974). With the use of vitamin K to control hemorrhage in the presence of 
jaundice, and due to difficulties in dealing with adhesions at the time of the second stage 
operation, it became evident that one-stage operations for radical PD would have definite 
advantages (Busnardo et al., 1983).  
In 1940 at New York’s Presbyterian Hospital, Whipple performed a distal gastrectomy on a 
non-jaundiced patient thought to have a gastric carcinoma. A group of visiting European 
surgeons watched the operation. At laparotomy, palpation confirmed the presence of a 
tumor and the stomach was transected in its mid-portion. When the tumor was recognized 
as pancreatic tumor and having to make decisions on the spot, Whipple proceeded with a 
one-stage resection of the head of the pancreas, including distal gastrectomy and resection 
of the entire duodenum. The transected pancreatic duct was ligated. The tumor proved to be 
a malignant glucagonoma, and the patient survived for 9 years (Howard, 2003). This 
procedure known to be the “Whipple operation” was reported five years later, and 
regarding the pancreatico-enteric reconstruction, Whipple recommended his then-current 
practice of duct re-implantation (Whipple, 1946; Whipple, 1963; Whipple, 1945). Unaware 
of the Whipple’s procedure, Trimble performed a similar resection a few weeks after, 
adding a distal gastrectomy to avoid blow out of the duodenal stump (Stafford et al., 1954). 
In the same year, Hunt added a pancreaticojejunostomy (PJ) to avoid leakage of the 
pancreatic stump (Hunt, 1941). 
In 1946, Whipple published his 10-year PD experience. In this report he proposed several 
modifications to the original procedure and advocated a one-stage procedure; oozing and 
hemorrhage could be controlled by preoperative vitamin K therapy, and a single procedure 
with continuous anesthesia and blood transfusion was safer than two major procedures 
(Whipple, 1946).  
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Table 3. Some important contributions to the development of pancreatic surgery. 
Gastrojejunostomy 
C. Roux. De la gastroenterostomie Rev Gynecol Chir Abdom, 1, 1897 
(Roux, 1897) 
First pancreatic head resection 
B. Dal Monte (1899). Rendiconto statistico della sezione chirurgica 
dell' Ospedale d'Imola, anno 1898. Galeati, 1899 (Dal Monte, 1899) 
Partial pancreatic head 
resection 
W.S. Halsted. Contribution to the surgery of the bile passages, 
especially of the common bile duct. Boston Med Surg J 141, 1899 
(Halsted, 1899) 
Pancreatic head resection (two-
stage) 
A.O. Whipple, W.B. Parsons, and C.R. Mullins. Treatment of Carcinoma 
of the Ampulla of Vater. Ann Surg 102, 1935 (Whipple et al., 1935) 
Pancreatic  head resection 
(one-stage) 
A.O. Whipple. Pancreaticoduodenectomy for Islet Carcinoma : A Five-
Year Follow-Up. Ann Surg 121, 1945 (Whipple, 1945) 
Pancreaticogastrostomy 
M. Waugh, and O.T. Clagett. Resection of the duodenum and head of 
the pancreas for carcinoma; an analysis of thirty cases. Surgery 20, 
1946 (Waugh & Clagett, 1946) 
Pancreaticojejunostomy 
R.B. Cattell. A technic for pancreatoduodenal resection. Surg Clin 
North Am 28, 1948 (Cattell, 1948) 
Total pancreatectomy 
L.S. Fallis, and D.E. Szilagyi. Observations on some metabolic changes 
after total pancreatoduodenectomy. Ann Surg 128, 1948 (Fallis & 
Szilagyi, 1948) 
Mesenteric superior vein 
resection 
G.E. Moore, Y. Sako et al. Radical pancreatoduodenectomy with 
resection and re-anastomosis of the superior mesenteric vein. Surgery 
30, 1951 (Moore et al., 1951) 
Central liver artery resection 
L.H. Appleby. The coeliac axis in the expansion of the operation for 
gastric carcinoma. Cancer 6, 1953 (Appleby, 1953) 
First larger series without 
mortality 
J.M. Howard. Pancreaticoduodenectomy: forty-one consecutive 
Whipple resections without an operative mortality. Ann Surg 168, 
1968 (Howard, 1968) 
Pylorus preserving resection 
L.W. Traverso, and W.P. Longmire, Jr. Preservation of the pylorus in 
pancreaticoduodenectomy a follow-up evaluation. Ann Surg 192, 
1980. (Traverso & Longmire, 1980) 
Extended resections 
J.G. Fortner. Surgical principles for pancreatic cancer: regional total 
and subtotal pancreatectomy. Cancer 47, 1981 (Fortner, 1981) 
Mortality  2% 
D.W. Crist, J.V. Sitzmann, and J.L. Cameron. Improved hospital 
morbidity, mortality, and survival after the Whipple procedure. Ann 
Surg 206,1987 (Crist et al., 1987) 
Centralization 
J.D. Birkmeyer, S.R. Finlayson, A.N. Tosteson, S.M. Sharp, A.L. 
Warshaw, and E.S. Fisher. Effect of hospital volume on in-hospital 
mortality with pancreaticoduodenectomy. Surgery 125, 1999 
(Birkmeyer et al., 1999) 
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Modern pancreaticoduodenectomy 
Although modified multiple times, the principles of Whipple’s operation have never 
changed. The gastric resection, originally the result of an error in diagnosis, remained as a 
part of the procedure until the pylorus preserving PD (PPPD) was described (Traverso & 
Longmire, 1980). In 1948, Cattell proposed an end-to-side PJ in order to reduce the 
incidence of POPF, which later became an established reconstruction technique (Cattell, 
1948). 
 
Centralization of pancreatic surgery 
In 1968, a series of 41 consecutive Whipple resections was reported, performed by one 
surgeon during a 13-year period without perioperative mortality and a fistula rate of 10% 
(Howard, 1968). In the publication, the importance of a dedicated clinical pancreatic team 
for successful patient management was emphasized. Despite these encouraging results, the 
Whipple's procedure gradually fell into disrepute due to excessive postoperative mortality 
and morbidity, procedure-dependent technical difficulties, and dismal long-term survival 
(Busnardo et al., 1983). The fact that comparisons of radical resections and bypass 
procedures of the obstructed bile duct did not reveal differences in long-term survival led 
some surgeons to conclude that resection for pancreatic cancers should be abandoned 
(Crile, 1970). However, the postoperative mortality after total pancreatectomy (TP) was 
reported even higher than in Whipple’s procedure in several series, although the 
pancreaticojejunal anastomosis was avoided (Tarazi et al., 1986).  
In 1981, a series of 146 patients from Mayo clinic reported for the first time a postoperative 
mortality below 5%, advocating for the continued use of the Whipple procedure (van 
Heerden et al., 1981). The publication was the prelude to a decade of centralization and 
systematic constitution of high-volume pancreatic centers resulting in larger series with 
similar mortality rates (Trede et al., 1990; Cameron et al., 1993). The reduction of mortality 
rates was regarded as a result of the concentration of operative experience and the 
improvement of supportive perioperative care (Howard, 2007). Regarding the remaining 
high morbidity rates, DGE accounted for half of the complications whereas the incidence of 
POPF varied from 0% to 30% (Ramacciato et al., 2011a). Complications following PD had 
also an impact on long-term outcome (Reddy et al., 2009). Some authors concluded that 
mortality rates below 5% and morbidity rates below 40% should constitute preconditions 
for experienced centers to perform PD (Orr, 2010). 
 
Extended resections 
Numerous efforts have been made to improve survival rates of resected PDAC by 
extending the PD resection. Although the first total pancreatectomy (Rockey, 1943), and 
the report of a successful total pancreatectomy for PDAC (Fallis & Szilagyi, 1948) was 
received with enthusiasm, the subsequent evaluation revealed disappointing short-term and 
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long-term results (Dresler et al., 1991). In 1951, Moore performed the first SMV resection, 
restoring continuity by re-anastomosis (Moore et al., 1951). In 1977, Fortner introduced the 
surgical concept of “regional pancreatectomy” in patients with advanced diseases (Fortner, 
1981), which included total or subtotal pancreatectomy and resection of adjacent arteries 
and veins. The operative mortality rate was high, and the procedure was not generally 
adopted. The report  that up to one third of PD patients had metastases in lymph nodes not 
usually removed with standard operation (Cubilla et al., 1978) resulted in an increased 
interest in the role of lymphadenectomy. In a retrospective study, an improved 5-year 
survival rate after extended lymphadenectomy was reported (Ishikawa et al., 1988). A 
subsequent randomized trial could not confirm these results, although patients with lymph 
node metastases had improved survival in the extended resection group (Pedrazzoli et al., 
1998). The study emphasized the need for defining the modern standard Whipple resection, 
including the extent of lymphadenectomy. A classification was proposed by a European 
Consensus Conference in 1998 (Pedrazzoli et al., 1999a).  
An extensive review of 340 studies revealed that only one out of 30 patients who underwent 
resection had a survival of five years or longer. A cumulative cost per ‘‘successful’’ 
resection was calculated (~$4.5M), and it was concluded that ‘‘pancreatic resections are 
wasteful of resources’’, emphasizing the need for procedure standardization and reporting 
(Gudjonsson, 1995). Also other authors considered the definition of standard techniques as 
crucial for outcome comparisons between institutions and for prospective RCTs comparing 
different procedure modifications (Jones et al., 1999). 
  
Indications 
Today, PD represents the standard of surgical care for patients with tumors originating from 
the pancreatic head, neck, uncinate process, duodenum or distal bile duct (Pedrazzoli et al., 
1999b). Apart from malignancy, the procedure is commonly performed for a wide array of 
indications ranging from benign conditions such as chronic pancreatitis, to pre-malignant 
lesions like intraductal papillary mucinous neoplasms, IPMNs (Balcom et al., 2001). PD is 
performed with the goal of achieving a complete tumor clearance with tumor-negative 
resection margins (R0). Referral to high-volume centers and surgeons is encouraged 
(Birkmeyer et al., 2006; de Wilde et al., 2012). Both the classic Whipple and PPPD are 
accepted techniques with similar outcomes (Diener et al., 2007; Iqbal et al., 2009). 
Extended lymphadenectomy has so far not shown improved survival (Michalski et al., 
2007). Portal vein resection has increased the number of patients amenable to resection, 
with equivalent survival rates compared with those of standard resections, and portal vein 
involvement is no longer considered a contraindication (Christians, 2009; Evans et al., 
2010). Resection and reconstruction of involved arteries have been too rarely performed to 
give evidence about possible surgical benefits in those selected patients (Matsuoka et al., 
2012; Mollberg et al., 2011). The pancreatico-enteric reconstruction has been the target for 
numerous RCTs and observational cohort studies (OCS); standards remain PJ and the 
pancreaticogastrostomy (PG).  
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Risk adjustment and outcome measurement 
Through its history, PD has been associated with a high morbidity. POPF was noted and 
documented in the first patients undergoing pancreatic surgery at the end of the 19th century 
(Whipple, 1946). Since then, prevention of POPF has been one of the main objectives in the 
research field of pancreatic surgery. Procedure centralization, one of the first successful 
measures to reduce morbidity, turned uncommon complex procedures into standard 
procedures. The idea of accumulating procedure volume in order to catalyze the 
development of knowledge and experience for uncommon procedures was not new, and its 
implementation had been documented early to result in improved outcomes (Howard, 1968; 
van Heerden et al., 1981; Donabedian, 1966; Mizumoto & Kawarada, 1980).  
 
Volume/outcome 
During the past decades, numerous studies have reported a strong volume/outcome 
relationship for pancreatic surgery, particularly for PD (Gooiker et al., 2011). In prevalence 
studies high-volume centers had lower in-hospital mortality rates (Birkmeyer et al., 1999; 
Gooiker et al., 2011; Teh et al., 2009; Eppsteiner et al., 2009; Birkmeyer et al., 2007), 
shorter hospital stay (Topal et al., 2007a) and improved long-term survival rates (Gooiker 
et al., 2011; Birkmeyer et al., 2007) compared to general surgical units. Longitudinal 
studies have showed that centralization of pancreatic surgery resulted not only in increased 
resection rates (Lemmens et al., 2011) and a reduction of postoperative mortality (de Wilde 
et al., 2012; McPhee et al., 2007; Gordon et al., 1998), but also in improved long-term 
survival (Lemmens et al., 2011). In contrast to the documented reduction of mortality, PD-
associated morbidity remains 20-50% (Ramacciato et al., 2011a), and the relationship 
between procedure volume and morbidity is not equally well documented (Dimick et al., 
2003). The lower mortality rates of high-volume centers could not be attributed to lower 
morbidity rates (Dimick et al., 2003; Allareddy et al., 2010). In fact, high-volume centers 
had morbidity rates similar to those of general units (Ghaferi et al., 2009), suggesting that 
more effective complication management or lower failure-to-rescue rates could explain the 
difference (Silber et al., 1997; Ghaferi et al., 2011). In the US, the increased focus on 
variations in surgical outcomes (Birkmeyer & Dimick, 2004; Birkmeyer & Birkmeyer, 
2006) has resulted in use of strategy models like selective referral, process compliance or 
outcome measurement in order to improve the quality of care (Birkmeyer & Dimick, 2009).  
 
Outcome measurement 
Outcome measurement has always been important in pancreatic surgery, not in the least to 
demonstrate the benefits of centralization (Birkmeyer et al., 1999), but only recently, more 
systematic standardizations of outcome parameters allowed meaningful comparisons 
between different surgical institutions (Dindo et al., 2004). Mortality is probably the oldest 
parameter used to evaluate surgical outcomes, and the term “in-hospital mortality” has been 
used for over 60 years (Ramberg, 1947). Subsequently, 30-days mortality had been 
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established as an alternative to in-hospital mortality. To capture the complete figure, several 
studies, mostly from the field of cardiac and thoracic surgery, have merged both parameters 
into “30 days or in-hospital mortality” (Shiraishi et al., 2006; Daebritz et al., 2000; Fremes 
et al., 1995; Handa et al., 2001). In pancreatic surgery, the great need for definitions in 
postoperative morbidity is illustrated by the numerous citations of available consensus 
definitions.  
Table 4. Examples of widely used classifications. 
Surgical complications 
D. Dindo et al. Classification of surgical complications: a new proposal with 
evaluation in a cohort of 6336 patients and results of a survey. Annals of 
surgery 240. (Dindo et al., 2004) 
Postoperative pancreatic 
fistula 
C. Bassi et al. Postoperative pancreatic fistula: an international study group 
(ISGPF) definition. Surgery 138 (Bassi et al., 2005a) 
Delayed Gastric 
Emptying 
M.N. Wente et al. Delayed gastric emptying (DGE) after pancreatic surgery: a 
suggested definition by the International Study Group of Pancreatic Surgery 
(ISGPS). Surgery 142 (Wente et al., 2007a) 
Postpancreatectomy 
hemorrhage 
M.N. Wente et al. Postpancreatectomy hemorrhage (PPH): an International 
Study Group of Pancreatic Surgery (ISGPS) definition. Surgery 142 (Wente et 
al., 2007b) 
SIRS 
R.C. Bone et al. Definitions for sepsis and organ failure, guidelines for the use 
of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference 
Committee. American College of Chest Physicians/Society of Critical Care 
Medicine. Chest 101 (Bone et al., 1992) 
 
One of the most widely accepted definitions of postoperative complications in surgery is 
the Clavién-Dindo Classification of surgical complications (CDC), which elegantly defines 
the severity of procedure-associated complications, i.e. procedure outcome, by the efforts 
made in order to control the complications (Dindo et al., 2004). The classification has 
during recent years been widely used in surgical reports (Clavien et al., 2009). 
Table 5. Clavién-Dindo Classification of surgical complications (Dindo et al., 2004). 
Grade I 
Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic, and radiological interventions 
Grade II Requiring pharmacological treatment, blood transfusions or total parenteral nutrition 
Grade III Requiring surgical, endoscopic or radiological intervention 
IIIa Not under general anesthesia 
IIIb Under general anesthesia 
Grade IV Life-threatening complication requiring IC/ICU management 
IVa Single organ dysfunction 
IVb Multiorgan dysfunction 
Grade V Death of a patient 
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Postoperative pancreatic fistula 
The dismal survival rates of resected PDAC are above all the consequence of unsolved 
disease-related and tumor-biological issues. They illustrate not only the surgical challenge 
of achieving R0 resections, but also the failure to develop methods of early cancer detection 
and effective adjuvant treatment. However, the poor short-term outcomes and high 
postoperative morbidity rates are mainly associated with insufficiencies in the surgical 
procedure. 
A postoperative pancreatic fistula is an abnormal communication from the pancreas to an 
epithelialized surface (Bassi et al., 2005a). POPF, typically caused by leakage from the 
pancreatico-enteric anastomosis (Butturini et al., 2006), constitutes the predominant cause 
of high PD-associated morbidity together with DGE (Ramacciato et al., 2011a; Tewari et 
al., 2010a). DGE is a common complication more accompanying rather than modifying the 
postoperative course. It may delay diet reinstitution and hospital discharge, and lead to 
persisting nutritional problems and impaired quality of life (Tani et al., 2006). In contrast, 
POPF is a dynamic complication that interferes with the postoperative course. It has the 
potential to induce severe secondary morbidity with sepsis and organ failure or lethal 
hemorrhage, high frequency of re-operations and increased associated mortality (Denbo et 
al., 2012; Fuks et al., 2009; Pessaux et al., 2011a; Yekebas et al., 2007; Shrikhande et al., 
2005). Even when controlled and successfully treated, POPF results in higher rates of 
readmission (Ahmad et al., 2012). Moreover, POPF has major social and economic impacts 
(Gudjonsson, 1995; Topal et al., 2007b; Enestvedt et al., 2012).  
The pancreatico-enteric anasto-
mosis has been labeled the 
“Achilles heel” of the procedure 
(Swope et al., 1994). Reported 
POPF incidences range from 0 to 
33% (Tewari et al., 2010b; 
Ramacciato et al., 2011b), 
reflecting  different POPF 
definitions  as much as any real 
difference (Ramacciato et al., 
2011b; Bassi et al., 2004).  Even 
studies using current standard 
definitions have reported POPF 
rates of between 15 and 26% 
(Reid-Lombardo et al., 2007b). 
Different terms have been used to 
identify POPF; fistula, leak, 
leakage, anastomotic failure, or anastomotic insufficiency. In a review of available 
literature from 1991 to 2000, 26 different definitions of pancreatic leakage were identified 
(Bassi et al., 2004). Applying the different definitions to a cohort of 242 patients, it was demonstrated that the incidence of POPF varied from 10 to 29% depending on the 
Table 6. Stages of clinically relevant POPF and associated 
mortality. Accumulating mortality with increasing 
severity and deterioration of patients with uncontrolled 
POPF  (Ansorge, 2010). 
Mortality 
Pancreaticoduodenectomy 3.5% 
↓ 24%  
Postoperative pancreatic fistula (POPF A/B/C) 13% 
↓ 79%  
Requiring additional drainage (POPF  B/C) 17% 
↓ 41%  
Requiring re-operation (POPF C) 33% 
↓ 60%  
Requiring ICU and additional intervention 40% 
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definition. As shown in table 1, the majority of reports investigating causes and risk factors of POPF use drain discharge (associated with amylase content), clinical signs, radiological parameters, and intraoperative findings as criteria to define POPF (Bassi et al., 2004).  
Table 7. Some established definitions of  POPF in recent literature.  
Drain output > 50 mL/day of amylase-rich fluid (> three times the serum amylase 
activity) on or after POD 7 
(Parviainen et al., 1996) 
Drain output > 50 mL/day of amylase-rich fluid (> three times the serum amylase 
activity) on or after POD 10 or radiological demonstration of pancreatic 
anastomosis disruption 
(Yeo et al., 1997b) 
 
Amylase level >1000 U/L in the drainage fluid collected from the peripancreatic 
drains and/or anastomotic disruption demonstrated radiographically. 
(Sato et al., 1998a) 
Drain output > 30 mL/day of amylase-rich fluid (> 5000 U) for more than 10 days (Buchler et al., 2000) 
Drain output >f 30 mL/day of amylase-rich fluid or at least 7 days beyond POD 4; 
confirmed by fistulography 
(Bassi et al., 2001) 
Drain output > 30 mL/day of amylase-rich fluid (> five times the serum amylase 
activity) on or after POD 5 
(Sarr, 2003) 
Drain output of any volume of amylase-rich fluid (> three times upper serum 
amylase) on or after POD 3 
(Bassi et al., 2005a)  
 
 
ISGPF definition and “clinically relevant fistula” 
The POPF definition that 
was provided by the 
International Study Group 
of Pancreatic Fistula 
(ISGPF) in 2005 is today 
widely accepted. The 
ISGPF defines POPF as a 
healing or sealing failure 
of the  pancreatico-enteric 
anastomosis or a 
parenchymal leak, which 
is characterized by an 
amylase concentration 
greater than three times 
the upper normal serum 
value in drain fluids on or 
after postoperative day 
three (Bassi et al., 2005a). Cases matching these criteria are classified into subclinical 
(grade A), clinical (grade B) or severe fistulas (grade C). The ISGPF fistula definition is not 
a tool for clinical decision making (Gebauer et al., 2012) but a retrospective reporting 
instrument facilitating inter-institutional comparison and standardization of outcomes in 
clinical translational research. The concept of clinically significant pancreatic leaks has 
been introduced in 1997 (Lowy et al., 1997); transferred to the ISGPF definition, multiple 
studies have merged the POPF-B and -C grades into a group of “clinically-relevant” fistulas 
(Reid-Lombardo et al., 2007b; Ansorge et al., 2012a; Facy et al., 2012; Moskovic et al., 
Table 8. Definition of Postoperative Pancreatic Fistula according 
to ISGPF. 
Clinical Criteria No fistula Grade A Grade B Grade C 
Drain amylase < 3 x > 3 x normal S-amylase 
Persistent 
drainage 
no yes 
Signs of infection no yes 
Readmission no yes / no 
Clinical condition well often well bad 
Specific 
treatment 
no yes / no yes 
US/CT no yes / no yes 
Sepsis no yes 
Reoperation no yes 
Death no yes 
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2010; Noji et al., 2012; Malleo et al., 2012). Aside from few experimental studies on the 
pathological mechanisms in the manifestation of POPF, the two main objectives within 
POPF research have been to identify risk factors for POPF (often in form of OCS) or to 
improve short-term outcome in preventive approaches (often in the form of randomized 
RCTs).  
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POPF risk factors 
Multiple risk factors for POPF following PD have been reported. In this thesis unalterable 
factors that have been observed to have an impact on POPF have been considered as risk 
factors, whereas procedure alterations with the intention to reduce POPF rates have been 
considered as POPF-preventive approaches (Machado, 2012). Factors with a reported 
impact on POPF can be divided into three categories: patient-related factors, disease-related 
(pancreatic) factors and treatment-related (surgeon-related or operative) factors (Lin et al., 
2004). 
 
Patient related risk factors 
Age and gender 
The reviewed literature is inconclusive regarding age or gender as risk factors for POPF. 
The majority of studies report statistically significant higher morbidity and mortality rates 
following PD in older patients when compared to younger patients, others show no 
differences (Ramacciato et al., 2011a). A retrospective review of 1891 PDs found that male 
gender correlated with POPF rate on univariate but not multivariate analysis (Lin et al., 
2004), while other reports did not confirm these findings (Cheng et al., 2007; DeOliveira et 
al., 2006). 
Obesity 
Obesity has been evaluated as a risk factor for morbidity following abdominal surgery 
(Mullen et al., 2008), and the impact of the body mass index (BMI) on PD-associated 
POPF rates has been investigated. A retrospective study of 92 standardized PDs showed a 
significant difference in POPF rates between obese (37%) and non-obese patients (15%), 
but no differences in other complications (Noun et al., 2008). The results of a series of 356 
PDs did not reveal significant correlations between BMI and POPF; however, the degree of 
visceral fat visualized on preoperative cross-sectional computer tomography imaging was 
significantly associated with higher rates of POPF and other complications (House et al., 
2008). A recent retrospective analysis of 240 PDs showed that obese patients undergoing 
PD had substantially increased blood loss and longer operative duration, whereas length of 
hospital stay or the rate of serious complications was not increased, the authors advocated 
not to preclude obese individuals from undergoing pancreatic surgery (Williams et al., 
2009). 
Cardiovascular disease 
Cardiovascular disease was correlated with increased POPF incidence in a study on 633 
consecutive PDs (DeOliveira et al., 2006), whereas coronary artery disease was found to be 
a significant risk factor for POPF in a prospective series of 131 patients (Lermite et al., 
2007). This was indirectly confirmed in a review of 1891 PDs demonstrating that patients 
with a history of coronary artery disease had a significantly increased likelihood of 
developing POPF (Lin et al., 2004). The authors explained the association by a decreased 
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visceral perfusion that resulted in anastomotic ischemia; alternatively that medications such 
as aspirin, β-blockers, etc. might compromise the anastomotic healing processes (Lin et al., 
2004). In contrast, arterial hypertension was found to be a protective factor for POPF 
(POPF incidence 14% in patients with high blood pressure and 44% in patients with normal 
blood pressure); according to the authors, arterial hypertension might help anastomotic 
healing by allowing improved visceral perfusion (Lermite et al., 2007). 
Diabetes Mellitus 
In the reviewed literature, studies have reported diabetes as both a risk and protective 
factor. In two prospective studies of 295 and 120 PDs, respectively, diabetes mellitus 
increased the probability of developing abdominal complications by a factor of seven 
(Cheng et al., 2007) and was associated with an increased POPF rate (Satoi et al., 2006); 
however, in a large retrospective study, preoperative diabetes mellitus was associated with 
a significantly lower POPF incidence (Lin et al., 2004). 
 
Disease related risk factors 
Histopathology 
The association between histological diagnosis and POPF development has been 
investigated by several studies. A retrospective study of 581 patients reported a POPF 
incidence of 27% for ampullary carcinoma compared to 5% for PDAC (Veillette et al., 
2008). The findings were confirmed in a series of 459 patients, reporting a POPF incidence 
of 13% for ampullary carcinoma compared to 5% for PDAC (de Castro et al., 2005a) and 
re-confirmed one year later (Satoi et al., 2006). In a sub-analysis of 303 patients of their 
large retrospective review, Lin et al. reported that CBD cancer was a significant predictive 
factor for POPF development (Lin et al., 2004). In a series of 233 patients ampullary, 
duodenal, cystic, or islet cell pathologies were suggested as independent risk factors for 
clinically relevant POPF (Pratt et al., 2008a). Other studies have confirmed an association 
between the histological diagnosis and POPF development (Kazanjian et al., 2005; Liang et 
al., 2007; Yeo et al., 1995). 
Pancreatic characteristics 
The most validated risk factors for POPF, soft parenchyma consistency (PC) or texture, and 
a non-dilated pancreatic duct are characteristics of a normal, unaffected pancreatic gland, as 
described in study II. In the current thesis, the terms “pancreatic consistency” and 
“pancreatic texture” are used synonymously in accordance with the reviewed literature. 
Soft PC and non-dilated pancreatic duct have also been associated with an increased 
production of pancreatic juice (Hamanaka et al., 1996), postoperatively elevated levels of 
serum C-reactive protein (Murakami et al., 2008) and high concentrations of drain amylase 
(Shyr et al., 2003; Okabayashi et al., 2007). The importance of soft PC as risk predictor has 
been known for almost 30 years; a soft PC was the main reason to favor a total 
pancreatectomy in order to avoid a difficult PJ (Brooks, 1976). That soft PC could 
constitute a risk factor for POPF was mentioned in a discussion by Longmire in 1984 
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(Longmire, 1984). Causative physiological mechanisms and the biological plausibility of 
soft PC being a risk factor for POPF were systematically investigated and discussed by Yeo 
(Yeo et al., 1995; Yeo et al., 2000). A ‘‘soft’’ or ‘‘normal’’ PC indicates a strong risk for 
the development of POPF, whereas a ‘‘hard’’ pancreas has been considered as a protective 
factor. A soft friable pancreas, more frequently seen in periampullary, endocrine, and cystic 
lesions, is characterized by the absence of fibrosis and the presence of edema and 
inflammatory cell infiltration into the pancreatic parenchyma. Technically, it is associated 
with difficulties in performing the pancreatico-enteric anastomosis (Brooks, 1976), whereas 
a hard fibrotic PC facilitates the construction of a good anastomosis (Yang et al., 2005). A 
fibrotic pancreatic remnant is thought to have reduced exocrine function, making it less 
likely to induce leakage of pancreatic juice (Ho et al., 2005). A soft pancreas was found to 
be associated with a higher incidence of POPF in both retrospective (Lin et al., 2004; 
DeOliveira et al., 2006; Liang et al., 2007; Okabayashi et al., 2007; Lee et al., 2007) and 
prospective studies (Ansorge et al., 2012a; Kamoda et al., 2008). Also the diameter of the 
pancreatic duct has been recognized to have a significant impact on the risk of POPF 
development by several reports, and small pancreatic duct diameter has been considered to 
complicate the construction of a safe pancreatico-enteric anastomosis (Crippa et al., 2007). 
In several retrospective series, pancreatic duct sizes less than 3 mm (Poon et al., 2007; Pratt 
et al., 2008b; Yang et al., 2011), less than 2 mm (de Castro et al., 2005a) or  non-visible 
ducts (Choe et al., 2008) were considered to be risk factors for developing clinically 
relevant POPF.  
A few experimental studies in 
the field (Tomaszewska et al., 
2000; Nevalainen & Aho, 
1992; Lamsa et al., 2008; 
Lamsa et al., 2009; Lamsa et 
al., 2006) provide valuable 
information on the causative 
mechanisms of POPF 
development. In an animal 
model it could be demonstrated 
that experimental transection 
with ultrasonic scissors or 
electrocautery induced more 
pancreatic injury than scalpel transection (Lamsa et al., 2006). The acinar cell damage and 
inflammation induced by the resection spread into the entire gland with intensity depending 
on the extent of injury at the site of transection (Lamsa et al., 2009). A high frequency of 
acinar cells in the cut edge of the pancreas (CEP) increased the risk for immediate 
postoperative complications following PD, whereas extensive fibrosis at the CEP proved to 
be a protective factor. The authors questioned the reliability of digital evaluation of 
pancreatic consistency and suggested that the risk for postoperative complications should 
be determined by histological analysis, proposing a CEP frozen section counting the 
number of acinar cells as stratification tool for future randomized RCTs (Laaninen et al., 
2012). 
Table 9. Causes and consequences of different types of 
pancreatic consistency. 
 Soft consistency Hard consistency 
Tumor pathology 
Duct non-
obstructive 
Duct obstructive 
Pancreatic 
parenchyma 
Normal 
Fibrosis, 
desmoplasia 
Exocrine function Normal 
Reduced / 
terminated 
Circulation / 
Perfusion 
Normal Reduced 
Suturing conditions Difficult Easy 
Acinar cells Normal Decreased 
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Treatment-related risk factors 
Neoadjuvant treatment 
One of the first studies on neoadjuvant radiation suggested that the treatment might prevent 
POPF after PD by demonstrating a POPF incidence of 5% in the radiation group and 19% 
in the conventional group (Ishikawa et al., 1991). A more recent retrospective study on 24 
patients undergoing neoadjuvant chemotherapy revealed no in-hospital or 30-day mortality, 
low surgical morbidity, and POPF occurring in one patient (Heinrich et al., 2008). A study 
comparing 46 patients undergoing neoadjuvant chemoradiation to 64 patients with 
conventional treatment showed similar POPF rates for both groups (Lowy et al., 1997). A 
study on 79 patients showed that neoadjuvant radiochemotherapy was associated with a 
marked reduction in the incidence and severity of POPF (10% vs. 43% in the control group) 
and associated morbidity (Cheng et al., 2006).  
Preoperative biliary drainage (PBD) 
The role of PBD as a risk factor for postoperative morbidity and POPF following PD has 
been discussed extensively. Unrelieved tumor-induced jaundice has been regarded as an 
intolerable symptom and a risk factor for postoperative complications. PBD was introduced 
in order to improve the patients’ preoperative quality of life and postoperative outcome 
(van der Gaag et al., 2009). However, PBD has been demonstrated to have its own risk of 
post-interventional morbidity, and the possible contamination of the biliary system by 
drain-introduced bacteria might contribute to postoperative infectious complications (van 
der Gaag et al., 2009). A randomized controlled multicenter trial advised against the routine 
performance of PBD (Velanovich et al., 2009). Retrospective studies demonstrated higher 
postoperative morbidity rates in patients undergoing PBD (Povoski et al., 1999). Two 
meta-analyses were inconclusive regarding the impact of PBD on the outcome of pancreatic 
surgery (van der Gaag et al., 2007; Saleh et al., 2002) and the POPF rate did not seem to be 
affected (Velanovich et al., 2009; van der Gaag et al., 2007). However, a recent 
randomized trial demonstrated significant increased complication rates after PBD (74%) 
compared to early surgery without PBD (39%), suggesting that routine PBD should be 
avoided (van der Gaag et al., 2010). 
Pylorus preserving pancreaticoduodenectomy 
Since the introduction of PPPD (Traverso & Longmire, 1980), numerous studies have 
compared this procedure to classic PD, including multiple RCTs and meta-analyses 
(Ramacciato et al., 2011a).Three systematic review and meta-analyses were published in 
the last two years, none of them could demonstrate the superiority of one procedure over 
the other in decreasing POPF rates (Diener et al., 2007; Iqbal et al., 2008; Karanicolas et 
al., 2007); both techniques are accepted and have similar POPF rates.  
Extended Resections 
Extended lymphadenectomy and retroperitoneal soft tissue clearance in association with PD 
were proposed as an option to improve long-term outcome and survival in patients with 
periampullary and pancreatic cancer (Farnell et al., 2005). The results of a multicenter RCT 
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of 81 patients did not reveal any differences in the incidence of POPF or other morbidity or 
mortality between standard and radical procedures (Pedrazzoli et al., 1998). A subsequent 
trial demonstrated significantly higher morbidity (43%) and a higher rate of DGE and 
POPF in patients undergoing extended resections compared to standard resections (29%); 
the survival being similar between the two groups (Yeo et al., 2002; Yeo et al., 1999). Two 
meta-analyses demonstrated higher morbidity rates following extended PD but no survival 
benefits (Iqbal et al., 2009; Michalski et al., 2007). 
Blood loss 
Several studies have investigated whether increased intraoperative blood loss could be a 
risk factor for POPF. A study on 233 PDs reported intraoperative hemorrhage greater than 
1000 mL to be a risk factor for clinically relevant POPF with a relative risk by a factor of 
nine compared to patients with limited blood loss (Pratt et al., 2008a). A study comparing a 
POPF group with a non-POPF group demonstrated that the POPF group had a significantly 
greater blood loss (1584 ± 862 mL) than the non-POPF group (794 ± 387 mL), proposing 
that blood loss exceeding 1500 mL implied an increased POPF risk (Yeh et al., 1997). A 
series of 295 PDs found a significant association between blood loss and intra-abdominal 
complications (Cheng et al., 2007). In a retrospective review of 1891 patients, increased 
blood loss and transfusions were associated with a higher POPF incidence (Lin et al., 
2004). Extended operative duration was found to be associated with POPF in three studies 
(Lin et al., 2004; de Castro et al., 2005a; Yeo et al., 1995). However, lack of standardized 
measurement and possible strong interactions with other relevant factors including more 
advanced stages of disease, patient obesity, jaundice-induced coagulopathy and concurrent 
pancreatitis could not be excluded (Yeh et al., 1997; Shrikhande & D'Souza, 2008; Lai et 
al., 2009). 
Intra-abdominal drainage 
Surgically placed prophylactic drains have been associated with increased rates of 
abdominal and wound infections, increased abdominal pain, decreased pulmonary function, 
and prolonged hospital stay in studies on other gastrointestinal procedures (Ramacciato et 
al., 2011a). Regarding PD, a retrospective study on 89 PDs comparing 38 patients without 
drains to 51 patients with routinely placed intraabdominal drains demonstrated similar rates 
of POPF, abscesses, reoperations and CT-guided interventions following PD, which led the 
authors to assume that routine use of prophylactic drains might not be necessary (Heslin et 
al., 1998). A subsequent RCT  of 179 patients could not demonstrate differences in 
mortality, morbidity, interventional radiologic drainage, or surgical exploration between the 
drainage and the non-drainage group, asserting that surgical drains following PD should not 
be considered mandatory (Conlon et al., 2001). A more recent prospective study on 104 
patients comparing early drain removal (POD 4) to delayed removal (POD 8) demonstrated 
a lower POPF-incidence in the early-removal group; however, the early removal group was 
enrolled consecutively after the delayed removal group and the results could have been 
influenced by increased surgical experience (Kawai et al., 2006). A randomized trial 
comparing early (POD 3) to standard drain removal (POD 5 or later) with deviant outcome 
criteria demonstrated that drains could be safely removed in patients at low POPF risk and 
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that prolonged postoperative drainage was associated with a higher rate of postoperative 
complications, increased hospital stay and costs (Bassi et al., 2010). However, several 
studies have emphasized the importance of drainage fluid analyses for the prediction of 
POPF (Facy et al., 2012; Molinari et al., 2007; Nissen et al., 2012; Shinchi et al., 2006; 
Sutcliffe et al., 2012; Winter et al., 2007).   
Postoperative nutrition 
The loss of gastric pacemaker activity following PD has been explained by the removal of 
the interstitial Cajal pacemaker cells with the duodenum and distal stomach, which, 
together with the physiological consequences of biliary and pancreatic diversion, resulted in 
a postoperative gastric stasis and DGE (Takaki, 2003). A recent systematic review of the 
current literature showed that routine total parenteral nutrition (TPN) was not beneficial and 
should be avoided (Goonetilleke & Siriwardena, 2006). It was demonstrated that early 
postoperative enteral nutrition was associated with a lower incidence and severity of 
infectious complications compared to TPN after pancreatic surgery (Di Carlo et al., 1999). 
The role of TPN in the development of POPF is barely studied; a retrospective analysis of 
50 PDs found that early postoperative administration of enteral nutrition was associated 
with a lower incidence of POPF (Okabayashi et al., 2007). 
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POPF-preventive approaches 
Various reconstruction techniques have been evaluated with the aim to reduce anastomotic 
leakage and the incidence of POPF following PD. These include different jejunal sites (end 
vs side), and different anastomosis types (duct-to-mucosa vs invagination) for the 
pancreaticojejunal reconstruction, as well as different organs for the pancreatico-enteric 
reconstruction (PG vs PJ). Moreover, the use of fibrin glue, pancreatic duct stents and other 
adjunct procedures have been investigated. RCTs on the technical modifications are rare 
(Yang et al., 2011), and as a result, there is no consensus about which operative technique 
is less prone to POPF development (Ramacciato et al., 2011a). A recent systematic review 
did not reveal one single pancreatic reconstruction technique to be applicable to all kinds of 
pancreatic remnants (Yang et al., 2011). 
 
Pancreatico-enteric reconstruction techniques 
Pancreaticojejunostomy 
PJ is the oldest and most commonly used technique of pancreatico-enteric reconstruction 
following PD. The jejunum is surgically easy to manage due to a good blood supply and a 
usually mobile mesentery. The traditional duct-to-mucosa PJ technique was first described 
by Cattell (Cattell, 1948) and later revised (Blumgart, 1996). The method re-establishes the 
flow of pancreatic juice in a near-physiological manner by uniting the remnant pancreas 
with a jejunal segment. The rationale behind the duct-to-mucosa technique was to obtain a 
direct communication between the pancreatic duct and jejunal mucosa in order to  protect 
the open CEP from the effect of proteolytic enzymes, and, thus to provide optimal healing 
conditions and prevent POPF (Shrikhande & D'Souza, 2008; Lai et al., 2009; Callery et al., 
2009). The anastomosis is considered as technically difficult to perform and was originally 
recommended for glands with dilated pancreatic duct; however, in recent years the 
technique has been preferred regardless of the duct diameter (Shrikhande & D'Souza, 2008; 
Lai et al., 2009; Stojadinovic et al., 2003).  
The invaginating end-to-end PJ is an established and well-proven alternative to Cattel's 
duct-to-mucosa technique that has been used for over 40 years (Aston & Longmire, 1974). 
In the early 70’s, there were four established alternatives to treat the remnant pancreas after 
pancreatic head resection; a pancreaticojejunal duct-to-mucosa anastomosis, an inversion of 
the transected end of the pancreas into the jejunal lumen, a ligation of the pancreatic duct 
with oversewing of the transected pancreas, or a TP (Aston & Longmire, 1974). During the 
past 30 years, the traditional PJ has been consistently reported to have an average POPF 
rate of 10% and ranging between 2 and 19% (Strasberg et al., 1997). Multiple variations of 
the PJ technique have been described; end-to-end PJ’s with invagination of the mobilized 
part of the remnant pancreas into the jejunum, end-to-side PJ’s with or without duct-to-
mucosa sutures, in antecolic or retrocolic jejunal loops, and with or without separation from 
the hepato-enteric anastomosis. One of the most recent variants is the binding PJ, which 
was originally reported to significantly decrease postoperative complications and POPF 
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rates when compared with the conventional PJ (Peng et al., 2007). The authors achieved 
excellent results with this anastomosis, but a subsequent validation of the technique was 
difficult (Maggiori et al., 2010; Buc et al., 2010; Kennedy & Yeo, 2011). According to a 
comprehensive review, the duct-to-mucosa anastomosis was regarded as a safer technique 
than invagination anastomosis (Poon et al., 2002). With small ducts and soft textures the 
POPF rate was lower in duct-to-mucosa PJ’s than in invaginated PJ’s (Suzuki et al., 2002). 
However, a prospective RCT could not demonstrate differences in morbidity or POPF rate 
between duct-to-mucosa and single-layer end-to-side anastomosis (Bassi et al., 2003). In a 
recent texture-and-duct-stratified RCT the lateral invagination technique had a considerably 
lower POPF rate than the duct-to-mucosa anastomosis (Berger et al., 2009). The conclusion 
was that additional studies were needed to define the optimal technique of pancreatic 
reconstruction following PD. 
Isolated Roux loop pancreaticojejunostomy 
Separation of the pancreaticojejunal and hepaticojejunal anastomosis by an isolated Roux 
loop reconstruction was advocated to avoid a bile-induced activation of pancreatic enzymes 
and thereby reduce anastomotic erosion (Kingsnorth, 1994; Khan et al., 2002; Sutton et al., 
2004; Kaman et al., 2008; Perwaiz et al., 2009; Ballas et al., 2010). Potential disadvantages 
were increased operating time and the need for an additional anastomosis. Several cohort 
studies had reported low fistula rates; however, recent studies could not reveal advantages 
over the traditional use of a single jejunal loop (Kaman et al., 2008; Perwaiz et al., 2009; 
Ballas et al., 2010). 
Pancreaticogastrostomy 
Since the technique was introduced in clinical practice (Waugh & Clagett, 1946), PG has 
been extensively investigated as a possible means of reducing POPF rates (Yeo et al., 1995; 
Sauvanet et al., 1992; Takano et al., 2000; O'Neil et al., 2001; Aranha et al., 2003; Bassi et 
al., 2005b; Duffas et al., 2005; McKay et al., 2006; Wente et al., 2007c; Bock et al., 2012). 
The inactivation of pancreatic enzymes by gastric acid and the absence of enterokinase in 
the gastric environment were considered as potential mechanisms that might contribute to 
preventing autodigestion of the pancreatico-gastric anastomosis. The thickness and rich 
blood supply of the stomach wall provided favorable conditions for suturing and 
anastomotic healing (Machado, 2012). However, three RCTs (Yeo et al., 1995; Bassi et al., 
2005b; Duffas et al., 2005) were unable to demonstrate significant differences between PG 
and PJ outcomes regarding POPF rates, other morbidity or mortality. The findings of a 
meta-analysis of 11 studies suggested that PG was safer after PD, but much of the evidence 
came from cohort studies (McKay et al., 2006). The results of a recent comprehensive 
meta-analysis indicated that all cohort studies reporting PG-superiority most likely had 
been influenced by publication bias (Wente et al., 2007c). In conclusion, the results of 
current research suggest that PG and PJ are techniques with equally good outcomes 
(Machado, 2012). 
  
27 
 
Gastric partition 
A PPPD with a technical modification of the pancreatico-gastric reconstruction (gastric 
partition), has been described (Fernandez-Cruz et al., 2008). A gastric segment, 12–15 cm 
in length, was prepared and placed in close proximity to the CEP, followed by the 
construction of an end-to-side, duct-to-mucosa anastomosis. The incidence of POPF was 
significantly lower in the gastric partition group (4%) compared to the PJ group (18%). 
According to the author, an advantage of this technique compared to conventional PG was 
the location of the anastomosis outside the gastric cavity so that contents could empty 
unhindered into the jejunum, and pancreatic juice could drain directly into the stomach 
(Fernandez-Cruz et al., 2008). At the time of writing this thesis, the modification has not 
yet been validated in other cohorts. 
Binding pancreaticogastrostomy 
Two problems with the binding PJ (Peng et al., 2004) were reported recently; discrepancies 
between the circumferential size of the remnant pancreas and the jejunal lumen, and the 
exudation of pancreatic juice caused by fixation sutures in the pancreatic capsule (Peng et 
al., 2011). In order to avoid these problems, a technical variant, the binding PG, was 
reported. The modification was designed and successfully performed with encouraging 
results, and considered as feasible for managing large pancreatic remnants (Peng et al., 
2011). At the time of writing this thesis, the modification has not yet been validated in other 
cohorts.  
Total Pancreatectomy 
TP allows a more extensive lymphadenectomy, obviates the risks of POPF and of positive 
pancreatic resection margins, but at the cost of intractable diabetes mellitus, compromised 
immunity, and complete loss of pancreatic exocrine function (Parsaik et al., 2010; Billings 
et al., 2005; Sarr et al., 1993; Karpoff et al., 2001). After its enthusiastic introduction 
(Fallis & Szilagyi, 1948), the following evaluation showed poor outcome results and TP as 
alternative to PD was abandoned (Andren-Sandberg & Ihse, 1983). Today, long-term 
outcomes are equally bad or even worse compared to pancreatic resection and a different 
but considerably impaired outcome profile makes TP an option to consider only in selected 
patients, but not with the aim to prevent POPF (Machado, 2012).  
 
Additional preventive surgical measures 
Optimizing blood supply to the pancreatic remnant 
A method to optimize the blood supply to the remnant pancreas is one of the modifications 
that have been reported to substantially reduce the POPF rate. The method is based on a 
concept of vascular watershed in the pancreatic neck and the significance of ischemia in the 
CEP for the POPF development. A series applying the method in PD patients resulted in a 
POPF rate of 1.6% (Strasberg et al., 2002). At present, the method awaits external 
validation. 
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Use of fibrin sealants 
An early RCT including 97 mixed resections showed no differences in POPF rates between 
the fibrin and non-fibrin groups (D'Andrea et al., 1994). A recent trial randomized 125 
high-risk pancreatic anastomoses to either application of fibrin glue sealant application on 
the anastomosis surface or not, with results showing similar POPF rates for both groups 
(Lillemoe et al., 2004). 
Pancreatic duct occlusion (PDO) 
Although being one of the oldest techniques to deal with the remnant pancreas (Whipple, 
1945), there is still no evidence that PDO could replace a pancreatico-enteric 
reconstruction. In a small series comparing PDO (primary closure of the pancreatic duct, 
oversewing of the pancreatic remnant and external drainage) to a PJ group, the PDO group 
had lower morbidity, decreased mortality, and shorter hospital stay (Reissman et al., 1995). 
A comparison of 86 chemical and suture occlusions of the pancreatic duct in 83 PJ’s 
revealed no significant difference in postoperative complications, mortality, or exocrine 
insufficiency. However, the PDO group had a significantly higher POPF rate (17% vs 5%) 
and a significantly higher incidence of postoperative diabetes mellitus after 3 and 12 
months, respectively (Tran et al., 2002). A RCT of 182 mixed pancreatic resections 
randomized to PDO with fibrin glue or conventional anastomosis could not reveal 
differences in POPF rates or other morbidity (Suc et al., 2003). 
Pancreatic duct stenting and external pancreatic drainage 
The rationale behind transanastomotic stenting was to protect the duct-to-mucosa PJ or PG 
from contact with pancreatic secretions; moreover it was considered to facilitate a more 
precise suture placement, and thereby to protect the pancreatic duct from suture injury and 
iatrogenic occlusion (Machado, 2012). However, stent obstruction and migration were 
significant drawbacks, and studies on pancreatic stenting revealed discordant results 
(Ramacciato et al., 2011a; Machado, 2012).  A cohort study on end-to-side PJ’s in soft 
pancreatic remnants comparing stented (internal or external) and non-stented methods 
showed no difference in POPF rates (Imaizumi et al., 2006). A randomized trial of 234 
patients showed that internal pancreatic duct stenting did not decrease incidence or severity 
of POPF (Winter et al., 2006). 
External pancreatic drainage or complete pancreatic diversion was thought to optimize 
anastomotic healing by preventing bile-induced activation of pancreatic enzymes 
(Machado, 2012). A cohort study showed equivalent outcomes for external and internal 
pancreatic stenting of duct-to-mucosa PJ (Ohwada et al., 2002). A RCT of 120 patients 
showed significant lower fistula rates in the external drainage group than in the non-stented 
group (Poon et al., 2007). A recent RCT of 158 patients randomized to external stent or 
conventional anastomosis revealed that the stented group had a significantly lower rate of 
POPF, overall morbidity, and DGE (Pessaux et al., 2011b). 
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Omental wrapping 
In order to protect surrounding organs from the autolytic activity of leaking pancreatic 
juice, vascularized structures such as the omentum or falciform ligament have been 
wrapped around the anastomosis. A recent nationwide survey of the Japanese Society of 
Pancreatic Surgery evaluated the POPF-preventive benefits of anastomosis-wrapping using 
the omentum or falciform ligament (Tani et al., 2012). Their analysis of 2597 cases could 
not reveal POPF reduction by omental wrapping (POPF 43% in the wrapping group, 37% 
in the non-wrapping group), and the incidence of clinically relevant POPF (B/C) was lower 
in the non-wrapping group (17% vs 22%). According to the authors, it was not possible to 
conclude whether the wrapping itself constituted a risk factor for POPF due to the 
retrospective character of the study (Tani et al., 2012). 
Surgical loupes 
Surgical loupes allow a precise reconstruction technique and minimize technical errors such 
as suture crossing, inadequate amounts of duct and jejunal mucosa or incorrect knot 
placement. Significantly reduced POPF rates with an operating microscope (3%) compared 
to operating loupes (15%) have been reported (Wada & Traverso, 2006). 
Surgeon volume 
Volume/outcome studies in complex surgical procedures have demonstrated that surgeons 
with higher caseloads achieve lower mortality and improved outcomes than general surgical 
units (Begg et al., 1998; Halm et al., 2002; Birkmeyer et al., 2002). High procedure volume 
was found to correlate with improved outcome following PD (Mukherjee et al., 2009; Ho & 
Heslin, 2003; van Heek et al., 2005; Balzano et al., 2008). A study of 145 PDs 
demonstrated a significant association between surgical volume and POPF incidence and  
reported low surgical volume as an independent risk factor for POPF development (Yeo et 
al., 1995). Similar findings were reported in a study comparing the outcomes of surgeons 
demonstrating an overall morbidity of 52% in PDs performed by surgeons with limited 
experience (less than 50 PDs) compared to and 27% for surgeons that had performed more 
than 50 PDs (Cheng et al., 2007). 
 
Preventive pharmacological approaches 
The pharmacological inhibition of the pancreatic exocrine secretion has been proposed to 
reduce the incidence of pancreatic fistula by multiple studies (Gurusamy et al., 2012), and 
the use of somatostatin or its analogues in order to prevent POPF after PD has been studied 
for over 20 years (Hackert et al., 2011b). The discordant results of multiple RCTs on the 
protective impact of prophylactic somatostatin were summarized in a recent Cochrane 
meta-analysis which concluded that the evidence in the current literature could not provide 
a recommendation about the routine use of prophylactic somatostatin or octreotide 
(Gurusamy et al., 2012).  
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Management of pancreatic fistula 
According to the reviewed literature, sufficient drainage and prevention of its progression 
are the cornerstones of managing POPF once the complication is recognized.  Appropriate 
treatment measures have to be instituted immediately and with highest priority (Bassi et al., 
2001; Yang et al., 2005; Shrikhande & D'Souza, 2008; Lai et al., 2009; Callery et al., 2009; 
Cameron et al., 2006). 
According to two series, non-operative management including treatment for postoperative 
bowel paralysis and drainage of intra-abdominal collections has been successful in about 
90% of cases (Kazanjian et al., 2005; Munoz-Bongrand et al., 2004). It has to be ensured 
that adequate hydration is provided; TPN is recommended in patients not having tolerated 
oral feeding after POD 10 (Yang et al., 2005; Shrikhande & D'Souza, 2008; Callery et al., 
2009). If  signs of infection are present, empiric antibiotics are recommended and adjusted 
according to gram stains or culture results (Machado, 2012). Cautious drain management is 
indicated in patients with POPF and high-output drainage (>200 ml/day) or amylase rich 
effluent (Bassi et al., 2001; Lai et al., 2009). The administration of octreotide with 
therapeutic intent has been recommended by some authors (Machado, 2012); however, 
according to a recent meta-analysis there is no solid evidence that somatostatin analogues 
result in a higher closure rate of pancreatic fistula compared with other treatments (Gans et 
al., 2012). In contrast, percutaneous drainage of  CT-verified collections has been 
considered to be crucial (Halloran et al., 2002). Post-pancreatectomy hemorrhage is 
favorably managed by angiographic embolization (Puppala et al., 2011; Sato et al., 1998b). 
Surgical intervention has to be considered in cases of suspected anastomotic dehiscence or 
in clinically deteriorating patients with non-drainable abscesses.  
Severe POPF leads to an accumulation of secondary morbidity and mortality (Denbo et al., 
2012; Fuks et al., 2009; Pessaux et al., 2011a) and remains an unresolved surgical problem. 
The prevention and management of severe POPF have been main objectives of recent 
POPF research (Pessaux et al., 2011a; Reid-Lombardo et al., 2007b; de Castro et al., 
2005a; Farley et al., 1996; Bachellier et al., 2008; Hasegawa et al., 2008; Blanc et al., 
2007; Ribero et al., 2013). Failure of conservative management might necessitate repeat 
surgery (Yekebas et al., 2007; de Castro et al., 2005b) but current treatment concepts have 
high failure-to-rescue rates (de Castro et al., 2005a; Ho et al., 2005; Farley et al., 1996; 
Bachellier et al., 2008; Ribero et al., 2013; Smith et al., 1992; Gueroult et al., 2004; van 
Berge Henegouwen et al., 1997). Surgical options include wide peripancreatic drainage of 
abscesses or fluid collections, revision of the initial pancreatico-enteric anastomosis, 
conversion to an alternative anastomosis, or completion pancreatectomy (Machado, 2012). 
In patients with PJ disruption, simple peripancreatic drainage might not be effective 
(Bachellier et al., 2008; van Berge Henegouwen et al., 1997). Completion pancreatectomy 
(CP), the standard treatment of severe POPF (Farley et al., 1996; Smith et al., 1992; 
Gueroult et al., 2004), has a high procedure-associated mortality (38-64%) and leads to 
complex secondary morbidity with poor short term and long term outcomes (Ribero et al., 
2013). 
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II OBJECTIVES 
The current thesis comprises two published papers and two submitted manuscripts. The 
general aims were to study the preconditions for developing clinically relevant pancreatic 
fistula following PD, and to propose POPF-predictive models that might facilitate the 
clinical management of patients undergoing PD. 
 
The specific aims were 
1. To evaluate the extent to which metabolite changes and protease activation in the 
proximity of the pancreaticojejunostomy provided pathophysiological information 
on the risk of postoperative pancreatic fistula formation after PD (study I). 
 
2. To assess the importance of postoperative analyses of pancreatic amylase in the 
contents of prophylactic intraabdominal drainage for the prediction of pancreatic 
fistula following PD (study IV). 
 
3. To develop a practical, structured PD-specific protocol for the intraoperative 
assessment of pancreatic gland consistency and main pancreatic duct diameter; and 
to evaluate the predictive impact of this assessment on the development of 
postoperative pancreatic fistula (study II). 
 
4. To assess the importance of procedure-specific risk factors for the risk adjustment 
of PD outcomes by comparing the predictive value of a procedure-specific 
pancreatic risk model versus an established generally applicable model consisting of 
other risk factors for postoperative morbidity and mortality (POSSUM, study III). 
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III PATIENTS AND METHODS 
All patients included in the cohort studies of this thesis underwent elective PD at the 
Department of Upper Abdominal Surgery, Karolinska University Hospital, Sweden, which 
is a tertiary referral surgical center for pancreatic diseases. The decision for surgical 
intervention was made at the Karolinska multidisciplinary pancreatic tumor board. The 
tumor board holds weekly structured conferences where surgeons, radiologists, oncologists 
and pathologists discuss each individual case and tailor diagnostic measures and treatments 
to the specific clinical context based on current evidence. Demographical and peroperative 
parameters were recorded prospectively during the preoperative surgical and 
anesthesiological evaluations that all patients had to undergo after the decision for surgery 
was made. The Pancreatic Intention-To-Resect Register (PITR) is a prospectively 
maintained database that is classified as an internal quality register. The register in its 
current form was started in January 2008 and includes demographics, operative parameters 
and postoperative morbidity data of all patients undergoing elective pancreatic surgery at 
Karolinska. 
 
Table 10. Study parameters. 
 
 Study I Study II Study III Study IV 
Identifier 
Microdialysis 
measurement 
Intraoperative risk 
assessment 
POSSUM risk 
adjustment 
Drain pancreatic 
amylase 
Design Prospective OCS Prospective OCS Prospective OCS Prospective OCS 
Data source µD database PITR + IPRA register PITR + POSSUM PITR + lab register 
Patients 48 110 195 315 
Recruitment non-consecutively non-consecutively consecutively consecutively 
Time period 
March 2007 – 
April 2010 
January 2008 – 
July 2010 
January 2008 – 
December 2010 
January 2008 – 
June 2012 
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Pancreaticoduodenectomy 
In all patients included in the studies of this thesis, a standardized Kausch-Whipple PD was 
performed with radical lymphadenectomy excluding stations 9 and 14d (Pedrazzoli et al., 
1999b). Selective sampling of station 16b1 (para-aortic nodes) was done for tumor staging. 
If considered necessary a resection of the superior mesenteric/portal vein was performed 
with curative intent.  
 
Resection 
The procedure followed a standardized sequence. A midline laparotomy provided adequate 
exposure of the resection field. The liver and peritoneal surfaces were examined for 
unexpected tumor dissemination (liver metastasis or peritoneal carcinosis). Suspicious 
lesions and enlarged lymph nodes outside the planned resection field were biopsied and 
examined by frozen section; if positive for dissemination, the resection was aborted or 
converted to a double bypass. The separation of the falciform ligament from the abdominal 
wall enabled the placement of a self-retaining retractor system (Omnitract®) in the 
laparotomy, which was affixed to the operating table beneath the left arm board. The caudal 
liver surface and the gallbladder were released from adhesions and the gallbladder was 
included in a liver retractor and reflected superiorly to provide adquate exposure to the 
subhepatic compartment.  
Pancreaticoduodenal mobilization 
The mobilization of the pancreaticoduodenal area started from right lateral by mobilizing 
the ascending colon and the hepatic flexure, in some cases extending to a Cattell-Braasch 
maneuver (Cattell & Braasch, 1960). Kocher’s maneuver was performed by reflecting the 
duodenum medially and separating it from the Gerota’s fascia and perinephric fat, 
developing the dissection plane down to the ventral aspect of the caval vein and left renal 
vein. The transverse mesocolon was retracted medially and separated from the duodenum 
and the uncinate process. The SMV was identified medial to the uncinate process in the 
root of the mesentery.  
The inferior medial mobilization of the pancreaticoduodenal area included a resection of 
the greater omentum and gastrocolic ligament which allowed a complete mobilization of 
the transverse mesocolon and exposure of the middle colic vein down to the SMV 
confluence. The whole infra-pancreatic portion of the SMV was exposed up to the inferior 
aspect of the pancreatic neck. The right gastroepiploic vein was ligated to prevent avulsion, 
while the large inferior pancreaticoduodenal branch to the SMV was preserved in order to 
avoid venous stasis in the specimen. An opening of the avascular plane between the anterior 
aspect of the SMV and the posterior aspect of the inferior pancreas was developed bluntly 
and the inferior portion of the pancreatic neck was undermined. 
The cranial mobilization of the pancreaticoduodenal area started with a cholecystectomy 
and the dissection of the cystic-duct/CBD confluence. The left hepatic artery (LHA) was 
34 
 
exposed in the hepatoduodenal 
ligament to its origin from the 
common hepatic artery (CHA). 
The extirpation of lymph node 
stations 8a and 12a allowed access 
to the central parts of the CHA and 
the anterior aspect of the PV. 
Potential anatomical variants of the 
right hepatic artery (RHA) had 
been identified preoperatively so 
that the CBD could be isolated 
from connective tissue while 
preserving the RHA. The CBD 
was divided 1-2 cm proximal to 
the cystic duct confluence. The 
distal lumen (specimen side) was 
sutured to limit potential spillage of cancer cells, while the proximal duct was left 
unclamped. The division of the CBD allowed exposure of the PV and access to the space 
under the proper hepatic artery (PHA), the GDA and the right gastric artery. After ensuring 
that pulsatile flow through the hepatic arteries was retained, the GDA was divided and 
suture ligated. The right gastric artery was divided and ligated. The CHA and the PV were 
exposed completely.   Superior pancreatico-duodenal branches to the PV were divided and 
ligated, and the PV was followed to the superior aspect of the pancreatic neck. The 
avascular plane between SMV and pancreatic neck was developed from the superior aspect 
and the pancreatic neck was undermined on the ventral SMV using a blunt instrument (“the 
forceps that does not exist”). The pancreatic neck above the SMV was sometimes looped to 
minimize pancreatic manipulation under the subsequent transection of the pancreas. 
The mobilization of the pancreatoduodenal area from the left was carried out by the 
transection of the stomach and the division of the jejunum. Transection points were chosen 
at the junction of the left and right gastro-epiploic arteries on the greater curvature and at 
the incisura angularis of the lesser curvature. The omentum was divided between the 
gastroepiploic vessels and the stomach was transected using a linear cutting stapling device 
(GIA®, Ethicon). The lesser omentum was divided and suture ligated. The stapler line of 
the remnant stomach was oversewn with continuous 4-0 PDS. The ligamentum of Treitz 
was opened and the jejunum was mobilized by full exposure of the duodenojejunal flexure. 
The jejunum was divided 10 cm distal to the ligamentum of Treitz with a GIA® stapler and 
the remnant jejunum was oversewn with 4-0 PDS. The proximal jejunal segment was 
devascularized and dislocated behind the mesenteric vessels through the duodenal fossa 
into the subhepatic compartment.  
Table 11. Michel Classification of anatomic variants of 
arterial liver blood supply. 
Type Arterial configuration Occurrence 
I 
Regular: 
CT – CHA – GDA / PHA – RHA / LHA 
84% 
II 
Replaced LHA: 
LGA – LHA 
1% 
III 
Replaced RHA: 
SMA – RHA 
6% 
IV Replaced LHA + RHA 0.5% 
V 
Accessory LHA: 
PHA – LHA1 and LGA – LHA2 
3.5% 
VI 
Assessory RHA: 
PHA – RHA1 and SMA – RHA2 
1% 
VII Assessory LHA and RHA 0 
VIII 
Replaced RHA + Assessory LHA 
or Replaced LHA + Assessory RHA 
0.5% 
IX Replaced CHA (SMA – CHA) 1% 
X Replaced CHA (LGA – CHA) 0 
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Pancreatic transection 
The pancreas was transected to the left of the SMV. Bleeding from the intrapancreatic 
arteries was controlled by electro cauterization or by hemostatic sutures with 6-0 
polypropylene. To separate the specimen from the mesenteric vessels the mesopancreas 
was transected usually using a lateral-inferior approach. At the inferior aspect, the first 
jejunal tributary vein was identified and preserved. The SMA could be identified usually 
posteromedial to the first jejunal tributary branch. After separating the specimen from the 
venous pancreaticoduodenal branches by individual clips ligations, the SMV was carefully 
retracted from the specimen by the assistant, allowing access to the retroperitoneal 
attachment of the uncinate process to the SMA. To achieve full tumor clearance the 
complete mesopancreas was separated from the SMA by exposing the SMA inferiorly and 
towards the aortic origin. The superior and inferior pancreaticoduodenal branches were 
divided and clips ligated. The para-aortic lymph node station 16b1 was sampled for staging 
purposes and the remaining nodes from station 12a, b and p were removed.  
 
Reconstruction 
For the pancreaticojejunal reconstruction, the remnant pancreas was mobilized above the 
splenic vein and the portal confluence. The proximal jejunum was advanced through a 
mesenteric defect that had been created to the left of the middle colic vessels. The 
pancreatico-jejunal anastomosis was carried out by a non-stented two-layer duct-to-mucosa 
PJ according to Cattel’s technique (Cattell, 1948). Both the outer (between the pancreatic 
Figure 1. Vascular structures in the hepaticoduodenal ligamnet and central mesentery.  
Patient with a Michel IX variant; a replaced CHA (branching from the SMA). 
PHA 
PV 
Pancreatic duct 
(non-dilated) 
Remnant pancreas 
(soft consistency) 
Splenic vein 
CHA 
IMV 
SMA 
SMV 
(wedge resection) 
Left renal vein 
Caval vein 
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parenchyma and jejunal seromuscularis) and inner (between the main pancreatic duct and 
the whole jejunal wall) layers were constructed as posterior and anterior rows of interrupted 
sutures with 5-0 polypropylene.  
 
When the ductal diameter was small, the inner layer was sutured with 6-0 polypropylene. 
The surgery was completed by a standard end-to-side single layer hepatico-jejunostomy 
using interrupted 5-0 polydioxanone (PDS) sutures according to the technique described by 
Blumgart and Kelley (Blumgart & Kelley, 1984), an antecolic stapled side-to-side 
gastrojejunostomy on a jejunal ‘omega’ loop, and a stapled side-to-side entero-enterostomy. 
Two four-channel Blake® drainage tubes were placed in front of the PJ and behind the 
hepaticojejunostomy. 
 
  
 
 
 
    
 
 
Figure 3. Inner and outer layers of the duct-to-mucosa pancreaticojejunal anastomosis. 
Blue lines indicate sutures. 
Jejunum Remnant pancreas 
Figure 2. Remnant pancreas with six duct sutures. Typical intermediate risk gland (dilated 
main duct and soft consistency). 
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Postoperative treatment 
In all patients in the four studies, the postoperative management followed a standardized 
protocol. The patients were evaluated twice daily by the attending surgeon in the high-
dependency unit or regular ward to identify possible deviations from the expected 
postoperative course. White blood cell count, serum levels of pancreatic amylase and C-
reactive protein were determined daily, along with the volume of drainage fluid and 
concentrations of drain pancreatic amylase.  Computed tomography was carried out if 
clinical symptoms or signs suggested the occurrence of an intraabdominal complication.  
Accessible fluid collections were drained percutaneously under ultrasonographic guidance. 
POPF, peripancreatic abscesses, and fluid collections with or without pancreatic amylase 
were treated equally according to a single standard care algorithm. Based on the patient’s 
clinical condition, this could involve a spectrum of radiological interventions and/or 
surgical procedures ranging from optimization of abdominal drainage to completion 
pancreatectomy. 
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Intraoperative pancreatic risk assessment 
In the studies II-IV, a PD-specific intraoperative pancreatic risk assessment (IPRA) was 
used to classify characteristics of the pancreatic gland, in order to relate those to the risk of 
developing POPF. After the pancreatic transection the consistency (PC) and the main 
pancreatic duct diameter (PDD) were assessed according to a four-grade scale for each 
variable. A PDD grade of 1 (more than 4 mm) was assigned when the lumen of the 
pancreatic duct at the point of transection exceeded the diameter of two 2-mm buttoned 
probes, a PDD grade of 2 (3–4 mm) when one probe could be inserted with room to spare 
but not enough to allow the insertion of a second probe, a PDD grade of 3 (less than 3 mm) 
when one probe would fit precisely in the duct, and a PDD grade of 4 (less than 2 mm) 
when a probe could not be inserted without significant force. In contrast to PDD, the 
surgeon’s PC assessment was subjective, based on visual and tactile information gathered 
during pancreatic manipulation, from mobilization and transection of the gland to 
mobilization of the remnant and placement of sutures during the pancreatico-enteric 
reconstruction. The PC grade was declared before the anastomosis had been completed. A 
PC grade of 1 was assigned for a very hard consistency (such as in patients with severe 
chronic pancreatitis), PC 2 for hard (fibrotic or atrophic obstructed pancreatic gland), PC 3 
for soft (unaffected compact gland), or PC 4 for very soft consistency (unaffected fatty 
pancreas). 
Table 12. Peroperative pancreatic risk assessment. Classification of pancreatic consistency (PC) 
grades and pancreatic duct diameter (PDD) grades. 
 
PC grade Subjective surgical assessment Risk factor 
PC1 (very hard) as in severe chronic pancreatitis no 
PC2 (hard) as in a fibrotic or atrophic obstructed pancreatic gland no 
PC3 (soft) as in an unaffected compact gland yes 
PC4 (very soft) as in an unaffected fatty gland yes 
   
PDD grade Surgical assessment with 2-mm buttoned probes Risk factor 
PDD1 (>4mm) PDD exceeds the diameter of two probes no 
PDD2 (3-4mm) One probe can be inserted with room to spare no 
PDD3 (<3mm) One probe fits precisely in the duct yes 
PDD4 (<2mm) A probe cannot be inserted without significant pressure yes 
 
Risk estimation of postoperative pancreatic fistula or associated morbidity. No risk factors - low 
risk for postoperative pancreatic fistula or associated morbidity (2%). One risk factor (softer PC 
or PDD < 3 mm) - intermediate risk (26%). Both risk factors (softer PC and PDD < 3 mm) - high 
risk (51%). 
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Microdialysis 
The blood concentrations of a substance may not reflect its concentrations at the cellular 
level; differences depend on the extent of protein binding, capillary permeability, and 
kinetics in the distribution volumes (Chaurasia et al., 2007). Microdialysis is an atraumatic 
minimally-invasive sampling technique of measuring concentrations of unbound substrates 
in the extracellular tissue fluid. The concept of microdialysis is based on attempts from the 
1960s to directly study biochemistry and notably transmitter release by using push-pull 
cannulas, dialysis sacs, and dialytrodes in animal tissues (Chaurasia et al., 2007). In 1974, 
the use of hollow fibers was reported (Ungerstedt & Pycock, 1974). A major breakthrough 
was the report on in situ microdialysis of the rat brain used to measure metabolic events at 
the cellular level; the atraumatic technique permitted stable dialysis conditions for several 
days (Zetterstrom et al., 1982; Ungerstedt et al., 1982). Improvements of this techniques 
resulted in the development of the microdialysis needle probe.  Microdialysis was rapidly 
used for pharmacokinetic studies and further adopted in clinical settings. Clinical 
microdialysis has been shown to be a safe and reliable technique for studying tissue 
biochemistry and drug distribution applicable to most organs in appropriate clinical 
situations (Ungerstedt, 1991; Muller, 2002). It is the only tool available that explicitly 
provides data on the extracellular space. Microdialysis methods have been used mostly in 
intensive care research, clinical pharmacology, dermatology and metabolic research 
(Chaurasia et al., 2007).  
The microdialysis technique requires the insertion of a probe directly or via a guide cannula 
into a specific tissue or fluid-filled space (Ungerstedt, 1991). The probe is designed to 
mimic a blood capillary. It consists of a shaft with a semipermeable hollow fiber membrane 
at the tip, which is connected to inlet and outlet tubing. Semipermeable membrane materials 
used in probe construction range from low- to high-molecular weight cutoff. A 
physiologically compatible perfusion fluid is delivered through the probe at a low and 
constant flow rate (0.1-5 μL/min). Solutes are exchanged by passive diffusion across the 
semipermeable membrane of the probe depending on the concentration gradient. By that, 
amounts of solutions can be sampled. Microdialysis has been widely employed in metabolic 
studies of various human tissues in vivo, particularly with regard to adipose tissue and 
skeletal muscle metabolism (Chaurasia et al., 2007; Magkos & Sidossis, 2005). 
In patients of study I, an intraperitoneal (IP) gastrointestinal microdialysis catheter was 
used (CMA 62, CMA® Microdialysis AB, Solna, Sweden) with a 180-mm shaft and a 30-
mm membrane in length, molecular weight cut-off at 20 kDa. After the intraabdominal 
drains had been placed, the catheter was introduced through a small incision in the 
abdominal wall and the microdialysis membrane was placed in the proximity of the PJ. The 
catheter outlet tubes were fixed to the skin. Microdialysis was performed as previously 
described (Jansson et al., 2003) starting at 12:00 pm on POD 1.  Samples were collected in 
microvials every 4 hours and were analyzed immediately for glycerol, lactate, pyruvate and 
glucose in a CMA 600 Microdialysis Analyzer (CMA® Microdialysis AB, Solna, Sweden) 
using a kinetic enzymatic analysis technique.  
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Blood levels of lactate and glucose were measured every 4 hours concomitantly with the 
microdialysis sampling. Trypsinogen activation peptide (TAP) was analyzed in 
microdialysates as a marker of protease activation on POD 1-2. Plasma pancreatic amylase 
was analyzed on POD 1-2. Postoperative complications were recorded according to the 
Clavién-Dindo Classification. Three study groups were stratified; the group of patients 
developing clinical POPF (ISGPF A-C and Clavién-Dindo ≥ II), a group a patients 
developing other surgical complications and a group without surgical complications.  The 
IP concentrations of glycerol, lactate, pyruvate, glucose, and TAP, and the systemic 
concentrations of lactate and glucose, along with the IP lactate/pyruvate ratio (L/P ratio), 
were compared between the study groups. 
 
Analysis of proteolytic activation peptides in microdialysates 
Since trypsin was too large (approximately 25 kDa) to pass through the membrane with a 
weight cut-off at 20kDa, other markers of proteolytic enzyme activation had to be 
evaluated. Enterokinase activates trypsinogen in the duodenum cleaving off trypsin 
activation peptide (TAP) with a molecular weight of 1 kDA. Trypsin in turn activates 
carboxypeptidase B cleaving off carboxypeptidase B activation peptide (CAPAP) with a 
molecular weight of 10 kDa. In a pilot subgroup of ten patients, TAP and CAPAP were 
analysed in microdialysates sampled from the pancreatic duct and duodenum during 
surgery and the IP microdialysates. TAP was measured by a radioimmunoassay and 
CAPAP by a double-antibody ELISA test (Appelros et al., 1998; Petersson & Borgstrom, 
2006). As expected (Rinderknecht, 1993b),  high levels of TAP were detected in the 
duodenum whereas it was absent in the pancreatic duct. Since TAP values were higher than 
CAPAP values, only TAP was measured in the rest of the patients. TAP concentrations 
were used to report IP protease activation, except in one patient with POPF, in whom 
CAPAP was detected but technical difficulties hampered TAP measurement. The analysis 
of TAP was performed in microdialysates stored at -20° C; TAP being a stable peptide 
could be stored safely at this temperature. 
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Postoperative drain and blood sample analysis 
In patients recruited into study IV, levels of serum C-reactive protein (CRP), an acute-phase 
reactant and marker of systemic inflammation, and plasma pancreatic amylase (PPA), a 
marker of pancreatic injury or inflammation, were recorded. From the 24-hour output of the 
abdominal drains concentrations of pancreatic amylase (DPA) were determined together 
with the respective drain volumes. The DPA levels that study IV refers to were obtained 
from the left abdominal drain. Drains were removed earliest on POD 4, if the drain volume 
was below 30-50 ml or if drain output did not contain amylase. The CRP concentrations 
were measured by an immunoturbidimetric assay and displayed as mg/L (normal range 0–3 
mg/L). The catalytic activity concentrations of PPA and DPA were measured by an 
enzymatic colorimetric assay after inhibition of the salivary-type α-amylase by monoclonal 
antibodies, and was displayed in katal (mol·s-1)/ L according to the International System of 
Units (Dybkaer, 2002). The SI unit formed the basis of all statistical calculations of PPA 
and DPA in the current study, the concentration of the enzyme unit (U/L) as adopted by the 
International Union of Biochemistry (1965, no authors listed) was calculated using the 
converting factor 1 U = 16.667 x 10-9 kat (Dybkaer, 2002). The normal range for PPA was 
0.15-1.1 µkat/L (9-66 U/L), and the lowest measurable level for pancreatic amylase was 
0.13 µkat/L (7.8 U/L), levels below that had been referred to as “<0.13” in the laboratory 
report and due to statistical reasons were defined as 0.12 µkat/L (7.2 U/L) throughout the 
study. 
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POSSUM score calculation 
The use of outcomes to address surgical quality implies the need for detailed clinical data 
for risk adjustment, either based on administrative systems (Charlson et al., 1987; 
Elixhauser et al., 1998) or on prospectively maintained clinical databases (Greenblatt et al., 
2011; Parikh et al., 2010a; Venkat et al., 2011).  In pancreatic surgery, different methods 
have been used for the risk adjustment of surgical procedure cohorts (Pratt et al., 2008b; 
Parikh et al., 2010a; de Castro et al., 2009; Grendar et al., 2012; Khan et al., 2003; Knight 
et al., 2010; Zhang et al., 2009; Tamijmarane et al., 2008).  
The well-established “Physiological and Operative Severity Score for the enUmeration of 
Mortality and morbidity” (POSSUM) estimates individual morbidity and mortality risk 
based on 12 parameters describing the patient’s clinical condition and on 6 parameters 
describing the extent of the surgical procedure (Copeland, 2002; Copeland et al., 1991). 
The complete scoring system is shown in table 13. The authors nominated the ratio between 
observed and POSSUM-estimated morbidity as quality indicator for surgical performances. 
The risk adjustment was recognized as most effective for general surgery  (Jones & de 
Cossart, 1999). Five years after its introduction, the logistic equation of the score was 
modified (P-POSSUM) due to mortality overestimation (Whiteley et al., 1996; Prytherch et 
al., 1998). Accordingly, variants were developed for several surgical sub-specialties (Dutta 
et al., 2011; Lam et al., 2004; Neary et al., 2003; Tekkis et al., 2004), however, not for 
pancreatic surgery. POSSUM, originally considered as suitable for pancreatic procedures, 
has subsequently been applied with divergent results (Pratt et al., 2008b; de Castro et al., 
2009; Khan et al., 2003; Zhang et al., 2009). However, it is still a widely used scoring 
system (Copeland et al.), and in 2010, it had been incorporated into the Swedish National 
Register for Pancreatic Tumors. An online POSSUM calculator is available at 
http://www.vasgbi.com/riskpossum.htm.  
In study III, all clinical, radiological and blood chemistry data required to calculate the 
POSSUM physiological score had been recorded at patient enrollment. Cardiac and 
respiratory criteria were evaluated based on the preoperative radiological work-up (CT-scan 
or chest X-ray). The parameters of the operative severity score were concomitantly 
recorded. PD was considered as “major+” (score 4) as originally proposed (Copeland et al., 
1991). Individual morbidity and mortality risks were calculated. Data recording and score 
calculation were done by a research fellow who was not involved in the surgery and blinded 
for the outcomes (P.L.).  
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Table 13. Physiological and operative assessment of the POSSUM system (Physiological and 
Operative Severity Score for the Enumeration of Mortality and Morbidity). 
 
 POSSUM score 
Physiological 1 2 4 8 
Age (years) <60 61–70 >70 NA 
Cardiac signs Normal Cardiac drugs Edema; warfarin JVP 
Chest X-ray Normal NA 
Borderline 
cardiomegaly 
Cardiomegaly 
Respiratory signs Normal SOB exertion SOB stairs SOB rest 
Chest X-ray Normal Mild COAD Moderate COAD Other change 
Systolic blood pressure  
(mm Hg) 
110–130 
131–170 
100–109 
>170 or 90–99 <90 
Pulse (b/min) 50–80 
81–100 
40–49 
101–120 >120 or <40 
Glasgow coma score 15 12-14 9-11 <9 
Urea nitrogen  
(mmol/L) 
<7.5 7.6-10 10.1-15 >15 
Sodium  
(mEq/L) 
>135 131-135 126-130 <126 
Potassium  
(mEq/L) 
3.5-5 
3.2-3.4 
5.1-5.3 
2.9-3.1 
5.4-5.9 
<2.9 or >5.9 
Hemoglobin  
(g/dL) 
13–16 
11.5–12.9 
16.1–17 
10–11.4 
17.1–18 
<10 or >18 
White blood cell count  
(x1012/L) 
4–10 
10.1–20 
3.1–3.9 
>20 or <3 NA 
Electrocardiogram Normal NA AF (60–90) Other changes 
     
Operative  1 2 3 4 
Operative magnitude Minor Intermediate Major Major+ 
No. of operations  
within 30 days 
1 NA 2 >2 
Blood loss per operation 
(ml) 
<100 101-500 501-999 >999 
Peritoneal contamination No Serous Local pus 
FBC, pus or 
blood 
Presence of malignancy No 
Primary cancer 
only 
Node 
metastases 
Distant 
metastases 
Timing of operation Elective NA 
Emergency <24 
h 
Emergency <2 h 
 
Adopted from the revised score (Copeland, 2002). JVP, jugular venous pressure; SOB, shortness 
of breath; COAD, chronic obstructive airway disease; FBC, free bowel content. 
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Main outcome parameters 
POPF 
In the studies of this thesis, POPF was defined according to the ISGPF definition (Bassi et 
al., 2005a). Different sub-criteria were used, among others, a widely used modification of 
the ISGPF definition; the categories of grade B and C were merged and labeled as 
“clinically-relevant fistula” (Reid-Lombardo et al., 2007b; Ansorge et al., 2012a; Facy et 
al., 2012; Moskovic et al., 2010; Noji et al., 2012; Malleo et al., 2012). The measurement 
of plasma pancreatic amylase instead of serum amylase was considered as unproblematic, 
since the ISGPF definition was based on the relation between the drain and serum levels of 
amylase, and serum and plasma levels of pancreatic amylase were considered as identical. 
 
Table 14. Main study outcome parameters. 
 Definition Paper 
Postoperative pancreatic fistula (POPF) 
ISGPF grade A-C IV 
ISGPF grade A-C and CDC ≥ grade II I 
ISGPF grade B or C II; III; IV 
Symptomatic peripancreatic collections 
(SPPC) 
Drainage improves patient condition 
regardless of amylase content 
II; III 
Pancreaticojejunostomy-associated 
morbidity (PJAM) 
POPF ISGPF grade B or C or SPPC II; III 
Severe pancreaticojejunostomy 
associated morbidity (PJAM) 
POPF ISGPF grade C or  
SPPC and CDC grade IIIb-V 
II 
Other surgical complications (OSC) 
Postoperative intra-abdominal 
complication CDC ≥ grade II 
I 
Total morbidity CDC ≥ grade II II; III; IV 
Mild morbidity CDC grade I-II III 
Moderate morbidity CDC grade IIIa III 
Severe morbidity 
CDC grade IIIb-IVb III 
CDC grade IIIb-V IV 
Mortality 
CDC drade V II; III 
CDC grade V or 30-days mortality IV 
 
ISGPF, International study group of pancreatic fistula, table 1; CDC, Clavién-Dindo 
Classification. 
 
SPPC and PJAM 
In study II and III, the ambition was to capture all relevant morbidity resulting from 
pancreatic surgery. Therefore, also radiologically verified postoperative abscesses or fluid 
collections not containing pancreatic amylase were recorded if they were adjacent to the PJ 
and if their drainage improved the patient’s condition; these were defined as symptomatic 
postoperative peripancreatic collections (SPPC). PJAM was defined as POPF (ISGPF grade 
B/C), or SPPC. 
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Clavién-Dindo Classification 
The Clavién-Dindo Classification of surgical complications adopted for pancreatic surgery 
(CDC) was used to classify postoperative complications (Dindo et al., 2004; DeOliveira et 
al., 2006). In study I, surgical complications other than POPF (OSC) were defined as any 
other postoperative intra-abdominal complication with a grade of II or higher according to 
CDC. In study II, severe morbidity was defined as CDC grade ≥ IIIb. In study III, the 
severity of postoperative morbidity was classified according to CDC, and morbidity was 
divided into mild (requiring bed-side treatment, CDC II), moderate (requiring additional 
intervention without general anesthesia, CDC IIIa), or severe (requiring additional 
intervention in general anesthesia and/or intensive care, CDC IIIb-IV). CDC V entailed in-
hospital mortality. In study IV, relevant postoperative morbidity was classified according to 
established definitions (Dindo et al., 2004; Bassi et al., 2005a; Wente et al., 2007a; Wente 
et al., 2007b; Bone et al., 1992).  
 
Mortality 
In study I-III, PD-associated mortality was defined as in-hospital-mortality corresponding 
to CDC V. In paper IV, PD-associated mortality was defined as either death occurring 
within 30 days after surgery (30-days mortality) or death in hospital, regardless of the time 
after surgery (in-hospital mortality). 
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Statistics 
Study I 
Data were presented as median and 10-90th percentile in graphs, and as mean with standard 
deviation as the measurement for statistic dispersion. The coefficient of variation between 
time points per day and patient indicated that it was appropriate to use the mean values as 
central tendencies for the analysis of aggregated data. Differences between groups were 
analysed by a two-way mixed model (Brown & Prescott, 2006) with study groups, POD 
and measurement type as factors. Logarithmic or square root transformations were 
performed before statistical analyses when needed. The Spearman rank correlation 
coefficient was used to measure the association between the metabolite variables. The study 
was considered to be a descriptive and explorative investigation and included neither power 
estimation nor randomization. P<0.05 was considered to be statistically significant.  
 
Study II 
The incidence and risk estimate of POPF and SPPC were calculated for each grade of PDD 
and PC. Patients were grouped according to PC and PDD characteristics. Based on the 
presence of risk factors, three groups were stratified: a group of no risk factors, a group 
with one risk facto and a group with two risk factors. Risk estimates for POPF, SPPC, 
PJAM and severe PJAM were determined for each group and reported as odds ratios. Two-
tailed Pearson’s correlation test and McNemar’s χ2 test were used to examine the 
association between PC, PDD and endpoint parameters. Interobserver agreement was tested 
using Cohen’s κ statistic.  
 
Study III 
POSSUM morbidity estimation calculates individual risk estimates based on a complex 
scoring system, and it can be difficult to interpret the predictive value of these individual 
scores. For a simplified risk categorization it has been assumed to group patients with 
similar scores. In accordance with previous publications (Pratt et al., 2008b; Zhang et al., 
2009) the study cohort was grouped based on the POSSUM morbidity risk into quintiles (0-
19%, 20-39%, 40-59%, 60-79% and 80-99%) which were labeled as standard risk (SR) 
groups. The cohort was additionally divided into low-risk (0-59%) and high-risk (60-99%) 
groups which were labeled as split cohort (SC) groups. Due to a non-normal patient 
distribution the cohort was further grouped into quintiles of near-equal sample size 
(POSSUM morbidity risk 0-48%, 49-59%, 60-69%, 70-75% and 76-99%) which were 
labeled as equal risk quintiles (ERQ). POSSUM mean values were calculated for the groups 
of SR, SC and ERQ and compared according to the observed morbidity. The ratio between 
observed and POSSUM-estimated morbidity (O/E ratio) was calculated. SR, SC and ERQ 
were correlated to total morbidity and severity of postoperative morbidity according to 
CDC. The study cohort was grouped by IPRA results, and the IPRA low-risk and high-risk 
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groups were compared to POSSUM low-risk and high-risk groups regarding total morbidity 
and CDC. Finally the associations between POSSUM SR groups, total morbidity and CDC 
were tested for the IPRA high-risk and low-risk groups, respectively. The associations 
between categorical variables were tested in binary logistic regression or by Pearson’s R 
bivariate correlation. The differences of distribution levels and medians in groups of 
continuous variables were assessed by Mann-Whitney U tests for two samples, and 
Kruskal-Wallis analysis of variance or independent median tests for several samples. 
 
Study IV 
Summary data were analyzed using frequency tables for category variables. The continuous 
variables were non-normally distributed (Kolmogorov-Smirnov and Shapiro-Wilk tests), 
therefore central tendency was displayed as median and statistic dispersion as interquartile 
range. Chi-square tests were used for comparing category variables, non-parametric tests 
(Kruskal-Wallis and Fisher’s exact for 5-sample, Mann-Whitney U for 2-sample) for 
comparing level distributions and level medians in continuous variables. To test the 
predictive accuracy (% of correctly predicted cases) receiver operating characteristic (ROC) 
analyses were performed. An area under the curve (AUC) greater than 0.8 was considered 
as of a high diagnostic accuracy, a p value <0.05 (two-sided) was considered as significant. 
Cut-off levels for the samples with the greatest AUC and a balanced high accuracy were 
identified by using the visualization and coordinates of the ROC-curve. Regression 
analyses for the cut-off-stratified subgroups were performed in order to identify risk models 
describing the dependent variable states with optimum accuracy. The actual risk estimates 
were reported as odds ratios. Postoperative day (POD) was displayed as subscript number 
after the sample name (PPA1 = plasma pancreatic amylase on the first postoperative day).  
 
Software 
The Karolinska Pancreatic Intention-to-Treat Register is a JMP® database. Statistical 
analysis was done using the SAS® System 9.1, (SAS Institute Inc., Cary, NC, USA) and 
Statistica 9.0, (StatSoft® Inc., Tulsa, OK, USA) in study I, using SPSS® 19 (SPSS, Chicago, 
Illinois, USA) in study II, using SPSS® 20.0 (IBM Corp., NY, U.S.) in study III and IV. All 
papers and the thesis were written using Microsoft Word® 2007/2010 and Adobe Acrobat® 
IX. References were managed using Thompson Reuters Endnote® 5/X6. Figures were 
scaled using GIMP 2.8.2. For literature search, NCBI Pubmed, Google Scholar® and the 
Karolinska Institutet library resources were used. Manuscript files were stored on Google 
Drive®. 
  
48 
 
IV RESULTS 
Study I 
Forty-eight patients were enrolled. Mortality was 4.1% (2/48) and overall surgical 
morbidity 31% (15/48). Seven patients (15%) developed clinically significant POPF. Two 
patients underwent CP on POD 4 and POD27, respectively, followed by ICU treatment. 
Five patients had clinical and radiological symptoms of POPF on POD 8-9; of those, one 
patient was treated successfully with intravenous antibiotics, two patients received IV 
antibiotics and ultrasound-guided drainage, and two were re-operated due to surgical 
complications other than POPF; one for bile leakage, and one for intra-abdominal 
hemorrhage. Eight patients had other surgical complications (OSC). One patient was re-
operated for leakage from the hepaticojejunostomy, three patients were re-explored due to 
suspected intra-abdominal bleeding; one patient was treated successfully by surgical 
hemostasis, one patient underwent a negative exploration, was re-operated for wound 
dehiscence and succumbed to circulatory arrest, and one patient died of multi-organ failure. 
Three patients with bleeding from the gastrojejunostomy were treated endoscopically. One 
patient developed a delayed leakage from the gastrojejunostomy.  
  
The POPF group had higher IP glycerol levels than the OSC (p=0.013) and NSC group 
(p=0.006, Fig. 1), while there were no differences in IP glycerol levels between OSC and 
NSC. The POPF group had higher IP L/P ratios than the OSC (p=0.049) and NSC group 
(p=0.024, Fig. 2), IP L/P ratios were similar in OSC and NSC. The POPF group had a 
significant increase in IP L/P ratios between POD 1 and 2 (p=0.003). IP lactate levels were 
higher in POPF compared with OSC (p=0.035) and NSC (p=0.015). IP glucose levels were 
lower in POPF than in OSC (p=0.014) and NSC (p=0.001). There were no differences in IP 
lactate and glucose levels between OSC and NSC. All groups had higher pyruvate levels on 
POD 1 than on POD 2 (p< 0.001). IP pyruvate levels did not differ between the groups. 
Figure 4. Intraperitoneal 
glycerol levels for POD 1-
5 following PD, grouped 
by POPF (n=7), other 
surgical complications 
(OSC, n=8) and no 
surgical complications 
(NSC, n=33). Median (10-
90 percentile) of median 
values for each time-
point in each of the 
groups are presented 
(line at median), *P<0.05, 
**P<0.01, ***P<0.001. 
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TAP and/or CAPAP were detected in microdialysates in six of seven patients with POPF. 
All patients had similar TAP levels regardless of the CDC grade. In 6 of 8 OSC patients, 
TAP was below 0.1 μg/L. In 31 of 33 NSC patients, TAP was below 0.1 μg/L on POD 1-2 
(table 15). Systemic lactate or glucose levels did not differ between groups or PODs. IP 
lactate levels were significantly higher than systemic levels on POD 1-5 (p<0.001, Fig. 3). 
Systemic glucose concentrations were significantly higher than IP levels in the POPF group 
(p< 0.001). 
 
Table 15. Intraperitoneal (IP) TAP and plasma pancreatic amylase (PPA). OSC (other surgical 
complications), NSC (no surgical complications). 
 
 
Total (n=48) POPF (n=7) OSC (n=8) NSC (n=33) 
IP TAP (µg/L) POD1 1.49 ± 8.24 11.18 ± 22.22 0.30 ± 0.78 0.001 ± 0.03 
IP TAP (µg/L) POD2 1.12 ± 6.23 8.63 ± 16.73 0.08 ± 0.25 0.002 ± 0.01 
PPA (µkat/L) POD1 2.02 ± 3.30 5.21 ± 5.96 1.55 ± 2.73 1.44 ± 2.22 
PPA (µkat/L) POD2 1.19 ± 2.02 2.44 ± 2.84 0.92 ± 1.87 0.98 ± 1.81 
 
  
Figure 5. IP lactate / 
pyruvate (L/P) ratio for 
POD 1-5 following PD, 
grouped by POPF (n=7), 
other surgical compli-
cations (OSC, n=8) and 
no surgical compli-
cations (NSC, n=33). 
*P<0.05, **P<0.01. 
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Study II 
A total of 110 patients were included in the analysis. There was excellent inter-observer 
agreement for both PC and PDD assessment in a series of ten consecutive patients (Cohen’s 
κ = 0.86). Sixty-eight patients (62%) developed postoperative complications and two (2%) 
died. Surgical morbidity was observed in 48 patients (44%) and pancreaticojejunostomy-
associated morbidity (PJAM) in 24 patients (22%). POPF, which occurred in 17 patients 
(15.5%; 9 ISGPF grade B, 8 grade C), was the most common complication and three-
quarters of these patients developed POPF-induced secondary morbidity. Patients with 
POPF had a significantly higher incidence of severe morbidity than patients with SPPC or 
other complications (8 of 17 vs 12 of 51; p=0.033). SPPC, the third most common comp-
lication (7 patients, 6.4%), was also associated with a high incidence of secondary 
morbidity (3 of 7 patients).  
 
POPF occurred in none of 23, one of 44, four of 16 and 12 of 27 patients with grades PC 1, 
PC 2, PC 3 and PC 4 respectively (p<0.001, fig 1). SPPC occurred in none of 23, two of 44, 
two of 16 and three of 27 patients with these grades (p=0.070). POPF developed in none of 
14, three of 50, ten of 37 and four of nine patients, and SPPC in none of 14, one of 50, five 
of 37 and one of nine patients, with duct diameter grades PDD 1, PDD 2, PDD 3 and PDD 
4 respectively (p<0.001, p=0.034, Fig. 2).  
When PC 1 and PC 2 were merged into a ‘harder PC’ group, and PC 3 and PC 4 into ‘softer 
PC’ group, the softer PC group had a significantly higher incidence of POPF (p<0.001) and 
a higher incidence of SPPC (p=0.071) than the harder PC group. When PDD 1 and PDD 2 
were merged into a ‘larger PDD’ group, and PDD 3 and PDD 4 into a ‘smaller PDD’ group 
(duct less than 3 mm), patients with a smaller PDD had a significantly higher incidence of 
POPF (p<0.001) and SPPC (p=0.015). Softer PC and smaller PDD emerged as risk factors 
for developing POPF or SPPC. Three different risk groups were defined; a group without 
risk factors (harder PC/larger PDD), patients with one risk factor (softer PC/larger PDD or 
harder PC/smaller PDD) merged into one risk group as they had identical risk profiles, and 
Figure 6. Incidence of 
pancreaticojejunostomy-
associated morbidity 
according to the various 
assessment grades of 
pancreatic consistency 
(PC) grouped into post-
operative pancreatic 
fistula and symptomatic 
peripancreatic collections. 
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a group with two risk factors (softer PC/smaller PDD). There were significant differences 
between the groups regarding the incidence of POPF (p<0.001), SPPC (p=0.019), PJAM 
(p<0.001) and severe PJAM (p=0.001). Patients with a high-risk pancreatic gland had a 25-
fold higher risk of developing associated postoperative morbidity than patients with a low-
risk gland. Severe PJAM developed in 20% of patients with two risk factors, in 11% with 
one risk factor and in 0% without risk factors. All patients with severe PJAM had a PDD 
smaller than 3 mm. The risk factor groups also had different distributions of histopathology. 
In patients with a high-risk gland, ductal adenocarcinoma was found in 17%, compared 
with 37% in intermediate risk patients and 73% in patients with low-risk glands. 
 
Table 16. Postoperative risk of pancreaticojejunostomy-associated morbidity. Incidence of 
postoperative pancreatic fistula (POPF) and symptomatic postoperative peripancreatic collections 
(SPPC). Patients grouped by presence of risk factors “soft pancreatic consistency” (SPC) or “small 
pancreatic duct diameter” (SPDD, < 3mm). 
 
 No Risk Factors 
One Risk Factor 
(SPC or SPDD) 
Two Risk Factors 
(SPC and SPDD) 
P 
POPF (B/C) or SPPC 2% 26% 51% < 0.001 
Odds ratio (95% CI) 0.025 (0.003 – 0.19) 1.4 (0.43 – 4.2) 12 (4.2 – 35)  
POPF (B/C) 0% 22% 37% < 0.001 
Odds ratio (95% CI)  1.7 (0.49-6.0) 10 (3.1-35)  
SPPC n  2% 5% 14% 0.019 
Odds ratio (95% CI) 0.14 (0.017 – 1.3) 0.79 (0.089 – 6.9) 6.1 (1.1 – 33)  
Severe POPF or SPPC  0% 11% 20% 0.001 
Odds ratio (95% CI)  1.4 (0.27 – 7.4) 9.1 (1.8 – 47)  
 
Severe POPF or SPPC is defined as POPF (B/C) or SPPC with a CDC ≥IIIb. 
 
Figure 7. Incidence of 
pancreaticojejunostomy-
associated morbidity 
according to the various 
grades of the pancreatic 
duct diameter (PDD) 
grouped into POPF and 
symptomatic peri-
pancreatic collections 
(SPPC). 
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Study III 
A total of 195 patients met the inclusion criteria for the analysis. One hundred twenty-six 
patients developed postoperative complications (total morbidity 65%); 33 of those (17%) 
were considered to have moderate, and 29 (15%) to have severe morbidity. The in-hospital 
mortality rate was 3.1%. POPF occurred in 30 patients (15.4%), delayed gastric emptying 
in 12%, systemic inflammatory response syndrome in 9% and SPPC in 7%. POPF and 
SPPC together accounted for the major part (22%) of the postoperative morbidity.  
The POSSUM algorithm 
calculated a mean 
morbidity risk for the 
study cohort of 62.5% 
(95% confidence interval 
61-65) and a mean 
mortality risk of 18.2% 
(95% CI 16.8 – 19.6). P-
POSSUM calculated a 
mean cohort mortality risk 
of 5.5% (95% CI 4.8 – 
6.2). With the observed 
morbidity of 65% the O/E 
ratio for the entire study 
cohort was 1.04. There 
were no systematic 
associations between 
estimated and observed 
numbers in the risk 
groups; the O/E ratio 
decreased with increasing 
morbidity risk since all 
risk groups had similar 
observed morbidity rates (table 5). The individual POSSUM scores did not reveal 
associations with the occurrence of postoperative morbidity (Mann Whitney, U=4326, 
p=0.956) or the severity according to the Clavién-Dindo classification (Kruskal-Wallis, 
p=0.908, Independent median, p=0.964).  
The IPRA groups showed significant differences in their morbidity profiles (table 7). The 
rates of total, moderate and severe morbidity in the high-risk group exceeded the rates in 
the low-risk group by a factor of 1.6-, 2.0- and 3.1, respectively. Mortality was 6% in the 
high-risk and 0% in the low-risk group. None of those differences were captured by the 
POSSUM risk estimates. Unadjusted and POSSUM-adjusted morbidity rates were found to 
be nearly identical. Patients with high-risk classified pancreatic glands did not have higher 
POSSUM scores than patients with low-risk pancreatic glands. 
 
Table 17. POSSUM groups, patient distribution, morbidity risk 
range, estimated and observed morbidity, ratio between 
observed and estimated morbidity (O/E ratio). 
 
  Morbidity  
POSSUM Groups N Estimated Observed O/E ratio 
Standard risk     
1 (0-19%) 0 0 0 - 
2 (20-39%) 19 6 (4-7) 14 (74%) 2.33 
3 (40-59%) 56 28 (22-33) 33 (59%) 1.18 
4 (60-79%) 92 64 (55-72) 58 (63%) 0.91 
5 (80-99%) 28 25 (22-27) 21 (75%) 0.84 
Equal quintiles     
1 (0-48%) 38 9 (0-18) 23 (61%) 2.55 
2 (49-59%) 37 20 (18-22) 24 (65%) 1.2 
3 (60-69%) 41 26 (25-28) 29 (71%) 1.12 
4 (70-75%) 32 23 (22-24) 21 (66%) 0.91 
5 (76-99%) 47 41 (36-47) 29 (62%) 0.71 
Split cohort     
Low-risk (0-59%) 75 22 (0-44) 47 (63%) 2.14 
High-risk (60-99%) 120 95 (72-119) 79 (66%) 0.83 
 
N displays number of patients assigned to the risk groups, 
‘Estimated’ displays number of patients with median estimated 
morbidity, group dispersion in parentheses. ‘Observed’ displays 
number of patients with observed morbidity, percent of each 
risk group in parentheses. 
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Table 18. Outcome parameters, morbidity profiles and POSSUM morbidity estimation in IPRA and 
POSSUM risk groups. 
 
POSSUM 
Intraoperative pancreatic risk 
assessment 
 low risk high risk P low risk high risk P 
 N=75 N=120  n=98 n=67  
Observed       
Total morbidity 47 (62.7) 79 (65.8) ns 49 (50) 56 (83.6) < 0.001 
Mild (DCC II) 23 (30.7) 36 (30)  31 (31.6) 18 (26.9)  
Moderate (DCC IIIa)  14 (18.7) 19 (15.8) ns 12 (12.2) 16 (23.9) < 0.001 
Severe (DCC  IIIb-IV) 9 (12) 20 (16.7)  8 (8.2) 17 (25.4)  
Mortality (DCC V) 1 (1.3) 5 (4.2) ns 0 4 (6) 0.015 
Surgical morbidity 29 (38.7) 62 (51.7) ns 29 (29.59) 46 (68.66) < 0.001 
POPFb 12 (16) 18 (15) ns 0 24 (35.8) < 0.001 
SPPCc 4 (5.3) 9 (7.5) ns 4 (4.1) 7 (10.4) ns 
DGEd 4 (5.3) 19 (15.8) 0.027 13 (13.3) 6 (9.0) ns 
Estimated       
POSSUM (95% CI) 46% (44-48) 73% (71-75) < 0.001 65% (62-68) 59% (55-63) ns 
P-POSSUM (95% CI) 2% (2-3) 8% (7-9) < 0.001 6% (5-7) 5% (3-6) ns 
 
Study cohort grouped by POSSUM-estimated morbidity risk into low-risk and high-risk, and 
grouped by the surgical pancreatic risk assessment into low-risk, intermediate-risk and high-risk. 
Intermediate-risk data not shown. POSSUM, physiological and operative severity score for the 
enumeration of morbidity and mortality. Values in parenthesis are percent and, if indicated as 
range, 95% confidence intervals. DCC, Dindo-Clavién Classification of surgical complications 
adopted for pancreatic surgery; POPF, Postoperative pancreatic fistula; SPPC, symptomatic 
postoperative peripancreatic collections; DGE, delayed gastric emptying. 
 
Patients with high-risk glands 
had no association  between 
the POSSUM SR group 
estimates and the observed 
incidence or severity of post-
operative morbidity (p=0.782 
and 0.486, respectively.). This 
was exemplified by a stepwise 
decrease of the O/E ratio 
concomitantly with increase 
of estimated morbidity (3.05, 
1.67, 1.16 and 0.98, 
respectively). However, in the 
low-risk group, associations 
between the SR groups and 
the incidence (p=0.44) and severity (p=0.026) of postoperative morbidity could be 
observed. This was characterized by a more constant O/E ratio in the SR groups (1.69, 0.62, 
0.79 and 0.74, respectively). 
 
Table 19. Association between POSSUM morbidity estimation 
and incidence and severity of total morbidity. Association 
between the peroperative pancreatic risk assessment (PPRA) 
risk groups and incidence and severity of total morbidity. 
 
 Total morbidity Clavién-Dindo 
 P P 
POSSUM risk estimation   
Individual POSSUM score 0.956a 0.908b 
Standard risk groups 0.637c 0.321d 
Equal cohort quintiles  0.950c 0.601d 
Split cohort 0.653c 0.319d 
PPRA groups < 0.001c < 0.001d 
 
aMann-Whitney test, bKruskal-Wallis analysis of variance, 
cRegression analysis, dPearson correlation 
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 Study IV 
Three hundred-twenty four out of 379 scheduled patients underwent PD (resection rate 
86%). Of those, 315 met inclusion criteria and were included in the analysis. Two hundred-
four patients (65%) developed postoperative morbidity, 18% considered severe (Clavién-
Dindo classification ≥ IIIb). Clinically -relevant POPF was the predominant primary 
morbidity occurring in 15%, and the associated mortality rate was 3.5%. A total of 76 
patients developed POPF according to the ISGPF definition. 17 patients with subclinical 
fistula (grade A, 5.4%) had a median length of hospital stay (14 days) comparable to those 
without POPF. Out of 59 patients with clinically-relevant POPF (grade B/C, 19%), 11 
developed POPF as a complication to another surgical morbidity. Of 23 patients with 
severe POPF (grade C, 7%), 7 were treated conservatively and 17 patients (5%) required a 
CP. Mortality in this latter group exceeded cohort mortality by a factor of 10. 
 
For POD1-2, CRP level distributions revealed significant differences between non-POPF 
and POPF-B and –C, and for POD3 between non-POPF and all POPF groups. In the non-
POPF group, the initial increase of CRP levels subsided after the first two postoperative 
days. Only 7% of patients with declining CRP levels after POD2 developed POPF-B/C, 
whereas 84.5 % of all patients with POPF-B/C had persistent or increasing CRP levels after 
POD2. PPA and DPA level distributions showed significant differences between non-POPF 
and all POPF groups for POD1-3. For the further analysis, subclinical fistulas (POPF-A) 
were assigned to the control group (non-POPF/POPF-A) and POPF-B/C was selected as 
dependent variable. Median levels of CRP, PPA and DPA for POD 1-3 differed 
significantly between non-POPF/POPF-A and POPF-B/C; median CRP in POPF B/C 
Figure 8. Levels of C-
reactive protein POD 1-4, 
grouped by POPF. Kruskal-
Wallis 5-sample calculated 
for POD1-3. Significant 
differences between non-
POPF and POPF-B/C on 
POD1 (p<0.05), non-POPF 
and POPF-A on POD3 
(p<0.05), non-POPF and 
POPF-B/-C on POD2+3 
(p<0.001). 
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exceeded median CRP in non-POPF/POPF-A by a factor of 2, median PPA and DPA levels 
of POPF B/C exceeded non-POPF/POPF-A by a factor of 6 to 62 (p<0.001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a receiver operating characteristic (ROC) analysis, CRP-, PPA- and DPA levels for POD 
1-3 revealed a high diagnostic accuracy for POPF B/C with an area under the curve (AUC) 
> 0.8 except CRP1 (figures 2a-c), and the highest accuracies for the levels of CRP3, PPA2, 
PPA3, DPA1 and DPA2.  Since POPF-prediction based on DPA3 levels could be confounded 
by the actual POPF definition, DPA3 was excluded from the cut-off analysis. In 21 
coordinates of the eight ROC curves the highest balanced accuracy (high sensitivity + high 
specificity) for POPF-B/C prediction was determined. Cut-off levels were selected for 
CRP3 at 202 mg/L (sensitivity 77.6%, specificity 83.1%, OR 16.978, 95% CI 8.425-
34.213), for PPA1 at 2.955 µkat/L (177.3 U/L, sensitivity 81.5%, specificity 75.7%, OR 
13.671, 95% CI 6.460-28.935), for PPA2 at 1.625 µkat/L (97.5 U/L, sensitivity 79.7%, 
specificity 81.2%, OR 16.972, 95% CI 8.328-34.590), for DPA1 at 18.115 µkat/L (1086.9 
U/L, sensitivity 83.6%, specificity 83.5, OR 25.818, 95% CI 11.686-57.039) and at 22.035 
µkat/L (1322.1 U/L, sensitivity 80.0%, specificity 86.0%, OR  24.606, 95% CI 11.551-
52.416), and for DPA2 at 5.235 µkat/L (314.1 U/L, sensitivity 87.8%, specificity 83.2%, 
OR 35.446, 95% CI 14.065-89.331) and at 7.125 µkat/L (427.5 U/L, sensitivity 83.7%, 
specificity 85.0%, OR 29.042, 95% CI 12.499-67.480). A multivariate regression of the 
parameters increased the specificity and thereby the accuracy for the POPF-B/C prediction. 
Four different prediction models were calculated. Model 1, solely based on PPA samples, 
Figure 9.  ROC-curve of drain 
pancreatic amylase levels for 
postoperative day (POD) 1-3; 
clinically relevant fistula 
(POPF B/C) as state variable. 
Area under the curve was 
0.891 on POD1 (95% CI 
0.847–0.935, p<0.001), 0.903 
on POD2 (95% CI 0.855–
0.950, p<0.001), and 0.933 
on POD3 (95% CI 0.897–
0.969, p<0.001). 
56 
 
identified many non-POPF patients. By stepwise regression, the sensitivity could be 
increased and the high specificity retained by substituting PPA1 with CRP3 (model 2). The 
DPA model was comparable to PPA2/CRP3 regarding the accuracy (88.5%) but had a 
stronger OR (31.885, 95% CI 13.945-72.906). The inclusion of PPA1 in the DPA model 
could not improve accuracy (86.1%), however, the inclusion of CRP3 (model 4) increased 
the sensitivity to 80% without impairing the specificity (92%), and by that the accuracy to 
90.3% (OR 44, 95% CI 16.889-115.379). The peroperative pancreatic assessment had a 
lower sensitivity and accuracy in predicting POPF than the selected cut-off levels of PPA, 
DPA and CRP. In fact, 37 out of 87 patients with high-risk glands developed POPF-B/C, 
yielding a sensitivity of 42.5% (accuracy 75.8%, OR 8.616, 95% CI 4.314-17.209), and 
adding intermediate-risk to the high-risk cases, 50 out of 143 patients developed POPF-B/C 
(sensitivity 35%, accuracy 64.4%). However, in patients with low-risk pancreatic glands the 
risk of developing POPF was negligible (1 out 121 patients with low-risk classified patients 
developed POPF, specificity of 99.2%, OR 64.516, 95% CI 8.750-475.713). 
Table 20. Multivariate binary logistic regression of plasma pancreatic amylase (PPA), serum C-
reactive protein (CRP) or drain pancreatic amylase (DPA) with selected cut-off levels. Different 
prediction models that describe the risk of developing clinically-relevant POPF following 
pancreaticoduodenectomy (odds ratio with 95% confidence interval). 
 
 Cut-off level OR (95% CI) Sensitivity % Specificity % Accuracy  % 
Model 1: PPA 13 (6.3-25) 51 92 81 
PPA1 3.0 µkat/L (177 U/L) 4.0 (1.4-11)    
PPA2 1.6 µkat/L (98 U/L) 5.3 (2.0-14)    
Model 2: PPA and CRP 19.0 (9.4-38) 65 91 86 
PPA2 1.6 µkat/L (98 U/L) 6.7 (3.0-15)    
CRP3 202 mg/L 7.4 (3.4-16)    
Model 3: DPA 32 (14-73) 64 95 88 
DPA1 22 µkat/L (1322 U/L) 6.5 (2.4-17)    
DPA2 5.2 µkat/L (314U/L) 11 (3.8-33)    
Model 4: DPA and CRP 44 (17-115) 79 92 90 
DPA1 22 µkat/L (1322 U/L) 6.6 (2.5-18)    
DPA2 5.2 µkat/L (314U/L) 6.2 (2.1-18)    
CRP3 202 mg/L 6.3 (2.5-16)    
 
Accuracy indicates % of correctly predicted cases. Subscript numbers specify the postoperative 
day when the sample is obtained.    
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V DISCUSSION 
The aims of this thesis were to elucidate the contributing factors and early diagnostic 
markers of POPF following PD, and to formulate predictive models that might facilitate a 
more individualized postoperative management of patients undergoing PD. In study I, local 
metabolite changes and protease activations in the proximity of the PJ were measured using 
intraperitoneal microdialysis technique. The profile that was seen in patients subsequently 
developing POPF (a combination of high glycerol, high L/P ratio and low glucose) was 
clearly distinct from the profile seen in patients with a normal postoperative course. In 
study II, a structured pancreatic assessment was proposed that provided a practical way to 
obtain good estimates of the risk of POPF or associated morbidity following PD. In study 
III, the capability of a generally applicable risk estimation model (POSSUM) in predicting 
incidence and severity of PD-associated morbidity was compared to that of the 
intraoperative pancreatic risk assessment model proposed in study II. The results 
demonstrated that POPF-associated risk factors assessed by the procedure-specific 
pancreatic model had stronger impacts on overall postoperative morbidity than the risk 
factors incorporated in POSSUM. In study IV, the data could prove drain pancreatic 
amylase at selected cut-off levels to be a superior diagnostic marker than plasma pancreatic 
amylase regarding the prediction of clinically relevant POPF following PD. A model 
combing drain pancreatic amylase (> 22 µkat/L or 1322 U/L on POD 1 and >5.2 µkat/L or 
314 U/L on POD 2) and C-reactive protein (>202 mg/L on POD 3) had the highest POPF-
predictive value.  
 
ISGPF definition 
The establishment of an internationally accepted definition of POPF provided by the ISGPF 
has been one of the major advances in POPF research. Multiple studies discuss 
postoperative pancreatic morbidity using the term “clinically relevant” fistula, which 
comprises ISGPF grades B and C, and excludes A-grade fistulae (Bassi et al., 2005a). In 
study II, it could be observed that ISGPF-defined clinically relevant POPF and clinically 
relevant peripancreatic fluid collections (not covered by the ISGPF definition) had similar 
associations with the discussed risk factors. This suggests an interrelationship between 
these differently defined morbidities at some level and a potential to enhance the sensitivity 
for the capture of relevant postoperative morbidity data, but the exact details of this have to 
be clarified. 
 
The general acceptance of the ISGPF definition has facilitated communication between 
pancreatic researchers. However, reviewing the recent literature, uncertainties in the usage 
of the definition may have contributed to some confusion. A more recent paper co-authored 
by one the ISGPF authors defined POPF as “output rich in amylase content confirmed by 
fistulography, stadiation by ISGPF” (Molinari et al., 2007) which is not consistent with the 
original definition. Reading the original definition carefully it says “Output via an 
operatively placed drain (or a subsequently placed, percutaneous drain) of any measurable 
volume of drain fluid on or after postoperative day 3, with an amylase content greater than 
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3 times the upper normal serum value” (Bassi et al., 2005a). However, multiple studies, 
among them one of the most systematic POPF reviews in recent literature refers to the 
ISGPF-definition as “POPF was defined as failure of healing/sealing of a pancreatic–
enteric anastomosis or a parenchymal leak not directly related to an anastomosis with a 
drain output of any measurable volume of fluid on or after postoperative Day 3 with an 
amylase content greater than three times the serum amylase activity” (Ramacciato et al., 
2011a). The discrepancy between upper normal serum value being an absolute value (in our 
institution 1.1 µkat/L or 66 U/L) and serum amylase activity being an individual and time-
dependent parameter may produce significant variations in the outcomes of PD and to some 
extent contribute to confusion in the understanding of the definition.  
 
Intraoperative pancreatic risk assessment 
In study II, a simple protocol for intraoperative risk assessment of pancreatic characteristics 
was demonstrated to have a significant predictive value on the subsequent development of 
POPF. Significantly higher incidences of general and severe pancreatic morbidity following 
PD were found in patients whose remnant pancreas had the risk factors of softer PC and 
PDD less than 3 mm. Of the patients with both risk factors, 51% developed associated 
postoperative morbidity in contrast to 21% with one risk factor and 2% without risk factors. 
The consistency and duct size assessment and classification into low-risk, intermediate-risk 
and high-risk glands revealed different relative risks of developing POPF by a factor of 25.
Table 21. Overview over studies investigating pancreatic risk factors for POPF after PD. 
Author, study type, 
patients/year 
(patients/years) 
Type of study, 
patients/year 
(patients/years), 
POPF 
definition 
Pancreatic risk factors 
PC classification p 
PDD 
classification 
p 
(Choe et al., 2008) 
R, 17 (172/10),  
POD 7 
no 0.392 non-dil./dil. 0.001 
(Pratt et al., 2008a) 
P, 42 (233/5.5), 
ISGPF 
soft/hard 0.001 1 mm decrease 0.011 
(Liang et al., 2007) 
R, 50 (100/2),  
ISGPF 
soft/hard 0.017 
3.4mm/ 
5.8mm 
<0.001 
(Poon et al., 2007) 
P, 20 (120/6),  
POD 3 
no 0.084 
≤3mm/ 
>3mm 
0.032 
(Yang et al., 2005) 
R, 15 (62/4),  
POD 3 
soft/hard 0.004 
<3mm/ 
≥3mm 
0.002 
(Okabayashi et al., 
2007) 
R, 3 (50/15), other non-fibr/fibr 0.01 no 0.14 
(DeOliveira et al., 
2006) 
R, 253 (633/2,5), 
POD 10 
soft/hard 
0.005 
 
no - 
(Lin et al., 2004) 
R, 12 (235/20),  
POD 10 
soft/mod/hard <0.001 no - 
 
R, retrospective; P, prospective; POD, postoperative day; PC, pancreatic consistency; PDD, 
pancreatic duct diameter; fibr, fibrotic. POD 7 (Yeo et al., 1997b); ISGPF (Bassi et al., 2005a); 
POD 3 (Buchler et al., 1992); POD 10 (Yeo et al., 1995). 
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Both characteristics, softer PC and smaller PDD, have been recognized as significant POPF 
risk factors by numerous previous reports (Pratt et al., 2008a; Liang et al., 2007); however, 
previous results are difficult to summarize due to the mixed use of endpoint definitions 
(Bassi et al., 2005a; Yeo et al., 1997b; Yeo et al., 1995; Buchler et al., 1992) as shown in 
table 8. Other problems are small study inclusion numbers per year (Lin et al., 2004; Liang 
et al., 2007; Okabayashi et al., 2007; Choe et al., 2008), retrospectively collected material 
from an extended time period, lack of standardized surgical protocols for the study cohort, 
several resection or reconstruction techniques (Lin et al., 2004; Liang et al., 2007; 
Okabayashi et al., 2007; Yang et al., 2005; Poon et al., 2007) or incomplete pancreatic 
characteristics data sets (Lin et al., 2004; Choe et al., 2008). Study II used standardized 
protocols, added clinically relevant parameters to the established endpoint definitions and 
proposed different pancreatic risk profiles that allow quantifying the risk of associated 
postoperative morbidity for each individual case. 
 
The original categorization of the pancreatic consistency and duct assessment to four grades 
was meant to provide an optimal demarcation between the grades, allowing a nuanced 
categorization, and resulting in groups comparable in size. It has repeatedly been shown 
that the surgical consistency assessment and classifications into “soft” or “hard”, despite of 
its subjectivity, is strongly associated with the histological grades of fibrosis (Reid-
Lombardo et al., 2007b; Wellner et al., 2010). The 4-grade scale for the subjective 
consistency assessment chosen in this study was meant to enforce a nuanced categorical 
decision-making by the surgeon avoiding an inconclusive “intermediate” category. The 
grading of the main pancreatic duct was done from a similar point of view based on earlier 
investigations on normal and dilated duct size (Hadidi, 1983; Hastier et al., 1998). In study 
II, 17% had one risk factor, either a smaller PDD (10%) with a hard consistency, or a softer 
PC (7.3%) with a larger PDD. Five patients of this subgroup (21%) developed associated 
morbidity (4 POPF, 1 SPPC), two patients that both had a harder PC developed severe 
complications. POPF-prediction based on pancreatic consistency alone would have 
substantially compromised the prediction sensitivity by missing 22% of all severe 
complications. All the 9 patients that developed severe pancreatic remnant-associated 
postoperative morbidity had a smaller PDD, regardless of the consistency. 
 
Limitations of POSSUM 
POSSUM was originally designed as a generally applicable ready-to-use risk scoring 
system for surgical procedures, and also suitable for pancreatic surgery. The intraoperative 
pancreatic risk assessment proposed in study II is a PD-specific tool for surgical decision 
making, designed to identify patients with a high risk for POPF, and based on validated and 
biologically plausible risk factors. POPF has been confirmed by multiple studies to be the 
predominant factor for postoperative complications following PD. In study III, the 
predictive impact of the intraoperative pancreatic risk assessment discussed in study II was 
tested on the same outcome parameters that are used for generally applicable risk 
adjustment models such as POSSUM. By comparing the morbidity predictions of both 
models, it was demonstrated that the risk factors incorporated into the intraoperative 
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pancreatic risk assessment had a significantly stronger predictive impact on the incidence 
and severity of overall morbidity than the factors incorporated into the POSSUM system. 
Also previous studies have raised conceptual issues concerning the predictive value of the 
POSSUM scoring system for pancreatic procedures. A series of 50 PDs reported morbidity 
overestimation and risk adjustment failure (Khan et al., 2003), and a series of 241 PDs 
morbidity underestimation and potential for systematic inaccuracy in predicting 
complications (Tamijmarane et al., 2008). In a series of 326 pancreatic resections with 
deviant outcome criteria, a correctly estimated cohort morbidity was observed but over- and 
underestimation were seen in low-risk and high-risk groups, respectively (Pratt et al., 
2008b), whereas in a series of 652 PDs a significant lack of fit was found (de Castro et al., 
2009).  The results of a recent review of 1734 pancreatic operations suggested that 
POSSUM overpredicted postoperative morbidity in patients undergoing pancreatic surgery, 
and both POSSUM and P-POSSUM failed to offer significant predictive value for mortality 
in pancreatic surgery. This had implications for clinical practice because there appeared to 
be insufficient evidence to promote the use of POSSUM in pancreatic surgery (Wang et al., 
2013). In study III, POSSUM underestimated postoperative morbidity in patients with a 
high risk for POPF and overestimated morbidity in low-risk patients. 
However, the idea behind POSSUM is still relevant. The ambition was to facilitate the 
assessment of surgical quality, allowing for comparative surgical audits to provide reliable 
outcome measures, and, in a wider perspective, to promote institutional transparency and a 
scientific environment in daily clinical practice. In the original report, POSSUM was 
introduced as a preoperative system “designed to predict the risk of morbidity or 
complications” (Copeland et al., 1991). In a re-publication, POSSUM was described as a 
“system developed to allow an assessment of surgical quality that was risk adjusted for the 
patient's acute and chronic physiological status and for the nature of the operation” 
(Copeland, 2002). These statements imply semantic differences in their definitions of 
POSSUM. In the reviewed literature, “morbidity prediction” and “risk adjustment” are 
often used synonymously; however, the terms have different origins and meanings. 
Morbidity prediction has been an objective in medical science and as a term, has also been 
used by health authorities. However, risk adjustment is a health-economic term that has 
been developed by insurance companies as an actuarial tool to calibrate payments to health 
plans or other stakeholders based on the relative health of the at-risk populations (Lodh et 
al., 2010). Available clinical data are converted into individual risk scores which are then 
aggregated into overall scores for each insurance plan. Risk adjustment has been developed 
as a method by which health insurance plans could be compensated based on the underlying 
health status of the people enrolled, and thereby protected against losing money by 
covering people with high-cost conditions. Much of the practical knowledge that exists 
about implementing risk adjustment comes from experience with the US Medicare program 
(Pope et al., 2000). In practice, individual risk scores, built from data on patient 
demographics, disability, institutional status, and diagnoses, are used to help determine 
monthly payments made to plans for each person enrolled in state Medicaid managed care 
programs. The POSSUM paper proposed an individual O/E ratio as an indicator for surgical 
performance. This individual ratio has some similarities to the individual risk scores used in 
health insurances. However, it is difficult to use or interpret in a clinical context. Medical 
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treatment or monitoring strategies cannot be dosed like payment plans. In contrast to the 
intraoperative assessment, POSSUM is not an instrument for clinical decision making as it 
depends also on postoperative data.  
Regarding risk adjustment for surgical audit, the use of a “one size fits all” system in a 
specific clinical context might have certain disadvantages. Some factors included in the 
score appeared to be limited by imprecise definitions, arbitrarily grouping, or are of 
questionable relevance. For instance, the routine use of preoperative chest radiographs is 
not generally accepted and rarely provides evidence to really modify therapy (Munro et al., 
1997). The risk scoring adjusted for systolic blood pressures has neither been proven to be 
predictive of perioperative cardiac events or other morbidities except for systolic pressures 
greater than 180 mm Hg (Casadei & Abuzeid, 2005). The grouping of hemoglobin or 
electrolytes levels appears to be irrelevant since chemical derangements are routinely 
corrected prior to elective or semi-acute surgery. On the other hand, conditions that have 
been associated with postoperative morbidity such as reduced cognitive function (Brooks-
Brunn, 1997), obesity (Archer & Jacobson, 1993; Littleton, 2012), creatinine as a marker of 
kidney function (Brooks-Brunn, 1997), or albumin, a marker of malnutrition and disease 
(Goldwasser & Feldman, 1997), have not been incorporated into POSSUM. Moreover, in 
the operative severity score, the terms “operation” and “procedure” suffer from imprecise 
definition. The malignancy scores have not proven to represent comprehensive risk factors 
for postoperative morbidity. Finally, POSSUM outcome criteria do not match current 
definitions and as a measure for surgical performance, the O/E ratio has not shown to be 
sufficiently robust in patient samples of smaller sizes. However, the idea behind the 
POSSUM score continues to be relevant. Centralization of complex surgery needs to be 
accompanied by an ongoing audit of results (Simunovic et al., 2010). Health care providers 
who benefit from centralization processes have to adapt to a greater demand of performance 
transparency and updated treatment standards to be able to provide credibility to buyers. 
Outcome measurement as a transparent method of quality assessment has become important 
even from an economic perspective (Birkmeyer & Birkmeyer, 2006), but a comprehensive 
interpretation of outcomes is dependent on a properly risk-adjusted patient cohort. This 
necessitates strict definitions, robust statistical processes and the identification of relevant 
risk factors. The results of the current study indicated that a useful risk adjustment model 
for pancreatic surgery needs to be procedure-specific, not generally applicable. 
 
Early diagnostic markers of POPF 
Local markers of subsequent POPF development 
Typically, intermediate- or high-risk classified pancreatic glands are not affected by duct-
obstructive processes and have an unimpaired exocrine activity. The early induction and 
persistence of the pancreatic inflammatory response to surgical trauma in unaffected glands 
has been demonstrated as a precondition for POPF development (Hashimoto & Ohyanagi, 
2002; Raty et al., 2006).  Accordingly, postoperatively elevated levels of drain amylase 
(Shyr et al., 2003; Okabayashi et al., 2007) or CRP (Murakami et al., 2008) have been 
demonstrated for pancreatic glands with soft PC and non-dilated duct (study II), and a 
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normal density of acinar cells and corresponding normal exocrine activity (Hamanaka et 
al., 1996). On the contrary, POPF risk decreased with increasing extent of fibrosis in the 
pancreatic remnant (Laaninen et al., 2012; Uchida et al., 2002).  That tumor-induced 
alteration of pancreatic parenchyma and duct diameter had protective effects against 
postoperative morbidity had been noticed already over thirty years ago (Brooks, 1976). A 
fibrotic firm texture and a dilated pancreatic duct constitute improved conditions for the 
construction of a duct-to-mucosa anastomosis; in addition, the diffuse parenchymal fibrosis 
seen after ductal obstruction might decrease pancreatic enzyme production and thereby 
lower the potential for POPF development (Kloppel et al., 2004). Other histological 
findings (duodenal/cystic/islet cell pathology) may be associated with a rather unaltered 
pancreatic gland but should not be considered as independent POPF risk factors (Pratt et 
al., 2008a).  
In study I and IV, consistent with these pathophysiological mechanisms, the pancreatic 
inflammatory response to the surgical trauma could be monitored by postoperative analyses 
of local metabolites near the PJ and of pancreatic enzymes in plasma and drains. However, 
it is unclear whether POPF establishes subsequent to the pancreatic inflammatory response 
or whether pancreatic inflammation and fistula formation might be concomitantly occurring 
processes. In study I, the levels of IP glycerol and TAP in microdialysate were initially high 
and then declined in the POPF group. The local presence of TAP close to the PJ could be a 
result of an enterokinase-induced trypsinogen activation at the intestinal brush border 
during the construction of the anastomosis (Rinderknecht, 1993b); alternatively of a 
premature intra-pancreatic trypsinogen activation, a process that may occur in the early 
phase of acute pancreatitis (Petersson & Borgstrom, 2006; Gudgeon et al., 1990; Lerch & 
Gorelick, 2000). The initial high and then rapidly declining glycerol levels could be caused 
by lipase activity or by cell membrane damage due to pancreatic transection and suturing.  
The low levels of IP glycerol and TAP measured in patients without POPF suggest a form 
of pancreatic inflammation to be involved in the early process of fistula formation. TAP 
concentrations were <0.1 µg/l in 31/33 patients with no surgical complications (NSC), and 
glycerol levels were below 100 μmol/l in patients with other surgical complications and 
NSC, similarly to previously reported levels in patients without complications after 
colorectal surgery (Jansson et al., 2005).  Previous investigations in colorectal surgery 
suggest that IP L/P ratios repeatedly exceeding 20, or an absence of a L/P ratio decline 
during the first postoperative days, may serve as indicators of visceral ischemia and 
subsequent anastomotic leakage (Jansson et al., 2004; Matthiessen et al., 2007).  In study I, 
the high IP L/P ratios in the POPF group could imply an impaired supply of glucose, which 
is the major provider of intracellular pyruvate. As a consequence, an impaired delivery of 
substrate and oxygen to the tissues shortly after surgery might predispose the subsequent 
development of POPF.  
The importance of drain amylase for the diagnosis of POPF 
The definition of POPF is based on the analysis of drain amylase (Bassi et al., 2005a), and 
the diagnostic importance of drain fluid analyses for POPF has been previously investigated 
(Facy et al., 2012; Conlon et al., 2001; Molinari et al., 2007; Nissen et al., 2012; Shinchi et 
al., 2006; Sutcliffe et al., 2012). However, based on the findings of study III, some issues 
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could be raised concerning previous conclusions on the subject. That a drain amylase (DA) 
cut-off level > 5000 U/L on POD1 could be used as indicator for POPF development, as 
proposed in a prospective study of 137 mixed pancreatic resections with ISGPF outcome 
criteria (Molinari et al., 2007), still needs validation in a PD-cohort (Sutcliffe et al., 2012). 
Evaluating drain pancreatic amylase (DPA), not DA, the present series could observe 
associations with POPF at significant lower levels but failed to confirm that one single 
DPA cut-off level from POD1 distinctly could separate POPF-courses from non-POPF. A 
retrospective study of 65 mixed pancreatic resections with ISGPF outcome criteria 
investigated drain lipase levels on POD 3 and 5, which correlated with DA levels, but had a 
higher sensitivity for POPF than DA (Facy et al., 2012). The current study avoided 
analyses of DPA samples from POD 3 or later, since the POPF-predictive impact of those 
analyses could be biased by the ISGPF-defined outcomes. Two cohort studies of 76 and 70 
PD patients, respectively, both with ISGPF outcome criteria, showed that the risk of POPF 
development was excluded and drain removal suggested for DA levels < 100 U/L (Nissen 
et al., 2012) or DA1 levels < 350 U/L (Sutcliffe et al., 2012), consistent with the findings of 
patients with intra-operatively classified low-risk pancreatic glands in the present study. A 
prospective cohort study of 177 mixed pancreatic resections and ISGPF outcome criteria 
showed that high rates of subclinical pancreatic fistula worsened the possibility of 
identifying clinical relevant POPF by analyzing DA postoperatively (Moskovic et al., 
2010). Published cut-off levels have to be validated in future studies but the monitoring of 
DA levels during the initial postoperative course revealed a POPF-predictive potential 
comparable to other more expensive methods (Ansorge et al., 2012b).  
The inherent effects of intraabdominal drainage on the outcome 
In several studies the therapeutic value of abdominal drains in pancreatic resections drains 
has been questioned. The use of drains could increase the incidence of postoperative 
complications (Conlon et al., 2001) and contribute to the development of infected intra-
abdominal fluid collections; early removal could reduce morbidity (Kawai et al., 2006; 
Bassi et al., 2010). Moreover, the absence of drains in pancreatic resections was not 
associated with increased risk of abscess, pancreatic or biliary fistula, postoperative 
interventions, reoperations (Heslin et al., 1998), morbidity or mortality; but with a 
decreased incidence of DGE and wound infections (Fisher et al., 2011). It was concluded 
that improvements in image-guided percutaneous drainage techniques allowed for safe 
post-operative drainage in patients who developed significant abdominal collections (Heslin 
et al., 1998), and therefore the routine use of abdominal drains was no longer considered 
mandatory (Conlon et al., 2001). It is difficult to assess whether these conclusions are valid 
for all POPF risk groups; as most of the study cohorts were heterogeneous in this aspect 
(Heslin et al., 1998; Conlon et al., 2001; Kawai et al., 2006; Fisher et al., 2011). According 
to a recent review the evidence regarding the effectiveness of prophylactic drainage after 
pancreatic surgery was still unclear and a treatment recommendation could not be given 
(Diener et al., 2011). In the current study, comparison with the results of the peroperative 
gland assessment emphasized the additional predictive value of the information gained 
from the drain analyses. Although not systematically investigated in the current study, a 
certain therapeutic value of abdominal drainage in these patients could not be disregarded. 
On the other hand, the risk of developing POPF was negligible in patients with intra-
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operatively classified low-risk pancreatic glands, and low or even undetectable DPA and 
PPA levels in this patient group reinforced this conclusion but had no additional diagnostic 
value. From that perspective and considering that it might be harmful after some days 
(Heslin et al., 1998; Conlon et al., 2001; Kawai et al., 2006; Bassi et al., 2010; Fisher et al., 
2011), prophylactic abdominal drainage following PD could not be recommended for 
patients with low-risk glands. 
 
Cum hoc non propter hoc 
In the past decades, RCTs testing different POPF-preventive approaches have produced 
discordant results, and observational cohort studies (OCS) have postulated risk factors that 
later did not materialize as relevant medical advances. The reporting of new risk factors and 
risk factor scoring systems has increased significantly in recent years. Nationwide 
databases such as the US NSQIP have facilitated systematic epidemiological and 
observational risk factor research which has resulted in complex risk factor reports (Parikh 
et al., 2010b). Indeed, the development of POPF is most likely a complex process, 
involving not only one single cause but multiple causal processes. However, knowledge of 
a risk factor does not automatically imply understanding the causation of a process. In other 
areas of medical research, it has been made clear that observational studies counting or 
scoring risk factors are important; however, they only initiate a process of fully elucidating 
pathophysiological causal chains (Kraemer et al., 2001).  
The term “risk factor” was coined by William B. Kannel in a 
publication of the Framingham Heart Study characterizing a 
condition that is correlationally, but not necessarily causally 
associated with an increased risk of disease (Kannel et al., 1961). The 
definition was rapidly adopted in numerous areas of translational 
medical research, and the terms “risk factor”, and in particular 
“independent risk factor”, have facilitated the reporting and 
publishing of associations.  However, their extensive use in POPF 
research might have resulted in an inflationary risk factor reporting 
with discordant results and unclear states of evidence. Consequently, 
the identification of reliable and relevant risk factors might have been 
hampered, and a focused research on the relevant causes of POPF 
development might have been delayed. In other research areas, an 
imprecise use of technical terms in risk research contributed to a certain confusion; more 
precise terminology would have revealed that most OCS actually evaluated correlates at the 
lowest level of causality, not risk factors, and by no means independent risk factors or 
causal factors (Kraemer et al., 2001; Kraemer et al., 1997). Minimal conditions required to 
establish a causal association between a factor and an outcome have been outlined in 
Bradford Hill’s Criteria of Causation (Hill, 1965), an accepted concept to evaluate  the 
quality of  associations in epidemiological studies. To test the quality of an association 
between a factor and an outcome, biological plausibility and temporal precedence have to 
Table 22. Terms 
used to 
characterize 
associations. 
Risk 
Risk factor 
Independent risk 
factor 
Causal risk factor 
Effect modifier 
Mediator 
Moderator 
Indicator 
Correlate 
65 
 
be confirmed, controlled confounders have to be accurately measured and further 
adjustment for potential unmeasured confounders has to be assessed.  
Due to their study design, OCS evaluating potential risk factors for POPF might be unable 
to determine the extent of confounding, bias, or chance expected. As a consequence of 
these assumptions, the subsequent designing of interventions to be tested in RCTs that 
manipulate correlates, not risk factors, is likely to produce inconclusive results. Regarding 
the concept of evidence based medicine this consequence might have been particularly 
problematic as grading systems placing RCTs at the top of a hierarchy might have delivered 
misleading conclusions in cases where RCTs 
were insufficient or unnecessary (Howick et al., 
2009).  
The many deviant results of studies in POPF 
risk factor research illustrate the need to 
completely elucidate the causal processes of 
POPF development. The pancreatic factors that 
were investigated in this thesis have been 
validated as risk factors for POPF by multiple 
studies and reach up to the level of “biologic 
plausibility” and “experimental evidence” 
according to the causation concept of Bradford 
Hill. They constitute essential factors to be 
considered in the risk adjustment of PD 
outcome measurement as well as in the 
stratification of study cohorts for future POPF-
preventive clinical trials.  
  
Table 23. Modified Bradford Hill Criteria of 
Causation. Strength of evidence in 
observational studies that supports 
causation (Johnson, 2012). 
1 Statistical significance 
2 
Strength of the association  
(odds ratio, relative risk) 
3 Dose–response relationships 
4 
Temporal sequence  
of exposure and outcome 
5 
Consistency of the association  
(internal validity) 
6 
Replication of results  
(external validity) 
7 Biologic plausibility 
8 Experimental evidence 
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VI CONCLUDING REMARKS 
Postoperative pancreatic fistula is the predominant morbidity following pancreatico-
duodenectomy. Until now, one single condition has been confirmed to fulfill the criteria to 
be an independent risk factor for POPF development at the level of biological plausibility: 
the preoperative physiological integrity of the pancreatic gland. An unaffected gland with 
unimpaired exocrine activity, typically characterized by a soft consistency and a small duct, 
responds to surgical trauma with a pancreatic inflammatory reaction. This response is 
monitorable by microdialysis of local metabolite concentrations in the proximity of the 
remnant pancreas or by analysis of pancreatic amylase levels in intraabdominal drainage.  
As a tool of surgical decision making, the intraoperative assessment of pancreatic 
consistency and pancreatic duct diameter represents a mandatory component in the 
procedure sequence of pancreaticoduodenectomy, and constitutes a step towards a tailored 
postoperative patient management. Intraoperatively, the identification of “high risk” 
characteristics may favor alternative surgical strategies for patients with poor clinical 
condition in whom POPF would be considered as a life-threatening complication; 
alternatively, when a primary POPF significantly increases the risk of inducing severe 
secondary morbidity due to the extension of the surgical procedure performed.  
Prophylactic abdominal drainage following pancreaticoduodenectomy is recommended in 
patients with intermediate or high risk classified pancreatic glands. Postoperatively, drain 
pancreatic amylase samples in combination with analyses of C-reactive protein can predict 
the subsequent or concomitant development of clinically relevant pancreatic fistula with 
high accuracy. The results of this thesis contribute to identifying patients in whom 
aggressive drainage strategies might be considered in order to prevent the development of 
severe fistula formation; however, this question should be addressed systematically in 
prospective randomized and POPF-risk adjusted clinical trials.  
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